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“Human beings don’t like things that are unexplained. We want the 
comfort and sense of safety that comes from predictability. Perhaps 
as we are evolved biological organisms, uncertainty is unsettling to 
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of causation. That’s what the idea of determinism represents in a 
simple, easy-to-grasp way. We want to be in control, to be able 
to manipulate nature to alleviate the problems that we face in a 
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causes, and that is perhaps why the metaphor of the gene as the 
atom of causation in life is so easy to absorb, and its subtleties so 
easy to overlook. We are made very uneasy by things that are only 
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on. When we can’t see it, and causation is many-to-many, that is far 
too much for our minds to deal with easily. Yet that seems to be the 
reality of the world.”
-Weiss & Buchanan, 2013-
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ABSTRACT
ABSTRACT
AIMS
The systemic levels of matrix metalloproteinases (MMPs) -7, -8 and -9 and the tissue 
inhibitor of metalloproteinase-1 (TIMP-1) were investigated in critically ill patients 
"'!"":;%/"'Q
the presence of neutrophil-derived MMP-8 in the infected organ compartment 
Q!//;:':/"
examine the association of neutrophil-derived MMPs -8 and -9 and their tissue 
inhibitor (TIMP-1) with outcome of critically ill patients. Finally, the effect of mild 
therapeutic hypothermia treatment on these variables was evaluated to determine 
their involvement in the therapeutic mechanisms of the treatment. 
PATIENTS AND METHODS
The study population comprised 877 patients. In Study I, 15 ICU-treated adult 
'';'/@!/
blood and urine samples were collected simultaneously on inclusion to the study. 
$$@>J;:""Q/""/!/"'
(IFMA). The serum and urinary levels of MMP-8 were compared with the peritoneal 
!/;%/";'"Q:"
;/%''';:!/'Q>
polyacrylamide gel electrophoresis. The main collagenolytically active protein was 
Q""/Q
Study II was a sub-study of the observational multicentre FINNSEPSIS study 
where patients with severe sepsis or septic shock were prospectively included in 
24 Finnish ICUs during a 4-month study period. The patient group of this study 
comprised 248 patients who consented to blood sample taking. Serum samples taken 
on admission to the study were analysed for MMP-8, MMP-9 and TIMP-1 levels 
by ELISA. The MMP and TIMP-1 levels were compared with those of ten healthy 
volunteers. Associations of MMPs -8 and -9 and TIMP-1 with ICU mortality were 
assessed by comparing the serum levels of survivors and non-survivors.
Study III was a retrospective laboratory analysis of 51 patients resuscitated from 
cardiac arrest. The patients were a subgroup of the Hypothermia After Cardiac Arrest 
study. Thirty of the patients had received mild therapeutic hypothermia treatment 
and 21 standard non-hypothermia treatment. Serum MMP-7, MMP-8, MMP-9 
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and TIMP-1 levels at 24 and 48 hours from restoration of spontaneous circulation 
(ROSC) were analysed. The serum levels of MMPs and TIMP-1 were compared 
between cardiac arrest patients and ten healthy volunteers. The association of 
hypothermia treatment was examined by comparing the serum MMP and TIMP-
1 levels of hypothermia-treated patients during and after hypothermia with the 
levels of nonhypothermia-treated patients. 
Study IV was a substudy of the FINNALI study conducted in 25 Finnish ICUs 
/J>@'/:/Q
for mechanical ventilation for more than 6 hours were included in the original study. 
Patients who consented to blood samples and who were not immunocompromised 
were included in this sub-study, which comprised 563 patients. MMP-8 and TIMP-
1 were analysed by IFMA and ELISA, respectively, from blood samples taken on 
study admission and 48 hours thereafter. Association of MMP-8 and TIMP-1 with 
90-day mortality and the discriminative power in predicting 90-day mortality were 
examined in all patients and in a subgroup of patients with acute lung injury or 
acute respiratory distress syndrome. 
MAIN RESULTS
High levels of collagenase recognized as mainly neutrophil-type MMP-8 were 
'!/:'%"
levels of MMP-8 in the sera and urine of the patients were elevated compared with 
;/$$$@>J;'  /"
/"!/ ; ::!/
did not intercorrelate.
Median MMP-8, MMP-9 and TIMP-1 levels were elevated in the serum of severe 
sepsis or septic shock patients compared with healthy controls. Higher median 
levels of MMP-8 (p<0.01) and TIMP-1 (p<0.001) were found in ICU non-survivors 
than in ICU survivors. MMP-9 levels were lower in non-survivors than in survivors 
(p=0.047).
Systemic MMP-8 and MMP-9 were elevated in cardiac arrest patients relative 
to healthy controls. Patients who received hypothermia treatment had lower 
median MMP-9 levels during hypothermia than non-hypothermia-treated patients 
(p<0.001). 
Serum MMP-8 poorly predicted 90-day mortality of acute respiratory failure 
patients. Admission TIMP-1 levels were higher in non-survivors than in survivors 
(p<0.001).TIMP-1 was an independent predictor of 90-day mortality, with a 
moderate discriminative power (AUC 0.633, 95% CI 0.580- 0.686). TIMP-1 was 
also associated with the severity of oxygenation disturbance. TIMP-1 levels were 
higher in the ALI/ARDS subgroup than in the whole cohort (p<0.01).
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ABSTRACT
CONCLUSIONS
The systemic levels of MMP-8 and MMP-9 are elevated in various groups of critically 
ill patients compared with healthy controls. Serum TIMP-1 increases in severe sepsis 
or septic shock patients, but reduced levels are seen after cardiac arrest compared 
'&;:$$@>J !/
of patients with secondary peritonitis, and they greatly exceed those measured 
simultaneously in serum and urine. Systemic MMP-8 is associated with increased 
ICU mortality in patients with severe sepsis or septic shock, but not with long-term 
mortality. Among severe sepsis or septic shock patients, lower levels of MMP-9 are 
associated with increased ICU mortality. Elevated TIMP-1 is associated with outcome 
in patients with severe sepsis or septic shock and in patients with acute respiratory 
failure. TIMP-1 is a potentially useful biomarker for predicting 90-day mortality in 
acute respiratory failure patients. Serum MMP-9 levels may be down-regulated by 
mild therapeutic hypothermia treatment. This is one potential mechanism for how 
mild therapeutic hypothermia affects outcome of cardiac arrest patients. 
KEY WORDS
Matrix metalloproteinase, tissue inhibitor of metalloproteinase-1, critical illness, 
"'!"";:';'/
failure, acute lung injury, post-cardiac arrest syndrome, therapeutic hypothermia, 
mortality
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1. INTRODUCTION
"'!"""<	=''Q/'
or leukopenia, fever or hypothermia, tachypnoea and tachycardia, is present in 
most patients requiring intensive care (Bone et al. 1992, Sprung et al. 2006, 
Dulhunty et al. 2008). In the case of sepsis, SIRS is triggered by infection, but 
also non-infectious insults such as pancreatitis, trauma, massive haemorrhage, 
burns and ischaemia-reperfusion injury may induce the syndrome (Bone et 
al. 1992). Mortality rates of equal magnitude have been reported for infectious 
>:'/ :	 <//J=% !""
response is initiated by the mechanisms of innate immunity, by recognition of 
damage (or danger)-associated conserved molecular patterns (DAMPs), which 
include pathogen-associated molecular patterns (PAMPs) and alarmins. Alarmins 
are various markers of tissue injury that are released by cells in distress or cells 
undergoing necrotic death (Bianchi et al. 2007). Pattern recognition receptors 
located on polymorphonuclear leukocytes, lymphocytes and macrophages mediate 
   /'/  '; ' : >!"" "
(Bianchi et al. 2007). In SIRS, the extremely complex biological cascades that are 
';/''""!""'
an uncontrolled manner in the whole body (Fry 2012). Activation of coagulation 
cascades, increased vascular permeability and loss of circulatory homeostasis lead 
to impaired tissue perfusion and oxygenation, organ dysfunction and ultimately to 
death of the patient. Although the amount of early organ dysfunction correlates well 
with outcome (Moreno et al. 1999), today’s intensive care provides sophisticated 
methods to support dysfunctioning organs, and the majority of patients survive the 
initial shock phase (Hotchkiss et al. 2006). Subsequently, most patients recover after 
":!""&;
on the degree of SIRS, some patients develop sustained organ dysfunction or failure, 
now the most common cause of mortality in critically ill patients (Knaus et al. 1985, 
Sprung et al. 2006). 
A host of preclinically promising therapies designed to pharmacologically 
"  !""  ; :  Q 	  
clinical studies in terms of improved survival, and therefore, the therapy principally 
remains supportive. In order to develop new therapies, it is important to further 
'"'":'!""
One of the proposed reasons for disappointing results in the originally promising 
pharmacotherapies is that the spectrum of the therapies has been narrow in view 
:  '" :  :   / !"" ''
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1. INTRODUCTION
Furthermore, inhibiting the initiators of the cascades may come too late considering 
clinical reality because patients often have full-blown SIRS upon presentation. 
Therefore, as well as the initiators, it may be useful to further explore the effectors 
!""''//'Q">
+';Q>!"""//
proteinases that, although necessary in eradication of the invading organism, have 
the capacity to cause direct collateral damage to tissues if the concentrations exceed 
those of their inhibitors (Owen et al. 1999). Among such proteinases are matrix 
metalloproteinases (MMPs) -8 and -9. Traditionally believed to play a role mainly 
in the processing of the extracellular matrix, they are now recognized as important 
/":!""'
MMPs participate in these reactions in almost all stages, beginning from 
chemotaxis and the transmigration of neutrophils from the circulation to the 
site of infection or tissue damage (Opdenakker et al. 2001, Vanlaere et al. 2009). 
Experimental evidence of the important roles of these enzymes in severe infection, 
!""'/Q>:'/Q/''
studies are still limited. There are several classes of pharmacological MMP inhibitors, 
and interestingly, the familiar and relatively safe tetracycline group of antibiotics 
inhibit the expression and activity of MMPs by a mechanism independent from 
their antimicrobial functions (Hanemaaijer et al. 1997, Golub et al. 1998). In animal 
/!""/Q/:/'':Q
alleviated or prevented by using pharmacological MMP inhibitors with a consequent 
/;;Q%/";Q'/"
patients due to differences between species, different timing of the inhibitor related 
to the triggering event and, especially considering sepsis, the incomplete equivalence 
between experimental models and human sepsis. Therefore, before moving on to 
clinical studies on MMP inhibition, more detailed information about the behaviour 
of these enzymes in association with critical illness is needed.
To evaluate the role of neutrophil-derived metalloproteinases in human 
SIRS, the studies included in this thesis investigated the systemic levels of these 
metalloproteinases and their regulators and inhibitors in different groups of critically 
ill patients. These groups included patients with severe infection, severe sepsis 
or septic shock, but also cardiac arrest patients to represent SIRS triggered by 
a different mechanism, namely ischaemia-reperfusion injury. To investigate the 
role of MMPs and their inhibitors in association with organ dysfunction, a group 
of patients with acute respiratory failure was included. The association of systemic 
MMP levels with outcome was examined, as was their usefulness as biomarkers in 
predicting mortality. In addition, the association of certain modes of therapy with 
the levels of MMPs and their inhibitors was evaluated. 
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Figure 1. Simpliﬁed schematic representation of systemic inﬂammatory response activated by 
damage-associated molecular patterns (DAMPs). The activated cascades lead to clinical representations 
and ultimately to organ dysfunction, which may further amplify the cascade via additional development 
of DAMPs by tissue ischaemia and necrosis. The phases in which MMPs have been suggested to 
participate are highlighted in red. Modiﬁed from Vanlaere et al. 2009 and Fry 2012. 
ACTIVATOR EVENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Tissue injury/Necrosis 
Ischaemia/Reperfusion 
Invasive infection 
 
DAMAGE-
ASSOCIATED 
MOLECULAR 
PATTERNS (DAMPs) 
ALARMINS 
 
HMGB1 
S100 proteins 
Heat-shock 
proteins 
IL-1 
Uric acid 
ECM components 
 
 
 
 
 
 
PATHOGEN-
ASSOCIATED 
MOLECULAR 
PATTERNS (PAMPs) 
 
Exotoxins 
Endotoxins 
Lipoteichoic acid 
Zymosan 
Flagellin 
Viral DNA 
 
 
 
INITIATORS 
 
Coagulation proteins 
Platelets 
Bradykinin 
Mast cells 
Complement proteins 
 
 
 
 
 
Vasodilatation (iNOS) 
Increased flow 
Increased permeability 
Oedema 
Pattern 
recognition 
receptors 
TLR, RAGE 
Activation of neutrophils 
Monocytes/Macrophages 
Cytokine burst TNF, IL-1, IL-6, 
IL-12, IFN-, IFN- 
Hypermetabolism 
Gluconeogenesis, Insulin 
resistance 
Fever 
Neurological abnormalities 
Chemoattractants 
Chemokines 
Adhesion 
molecules Systemic margination and 
activation of neutrophils 
Decreased neutrophil 
apoptosis 
Release of granule 
contents 
Endothelial activation and injury 
Microcirculatory vasoconstriction 
Microcirculatory thrombosis 
Oxidative damage, ROS, RNS 
Lysosomal enzymes 
Neutrophil proteinases 
 -Elastase 
 -MMP-8 and MMP-9 
 -Myeloperoxidase 
ORGAN DAMAGE 
16
2. REVIEW OF THE LITERATURE
2. REVIEW OF THE LITERATURE
2.1. EXTRACELLULAR MATRIX, NEUTROPHIL-DERIVED MATRIX 
METALLOPROTEINASES AND THEIR REGULATION 
2.1.1. EXTRACELLULAR MATRIX (ECM)
The extracellular matrix is an important playground of matrix metalloproteinases. 
The ECM is an acellular component of tissue consisting of interstitial collagens I, II 
			'Q'Q"""Q'"'
IV, laminin and entactin. It also contains hyaluronan, which participates in the 
regulation of cell adhesion, migration and signalling (Stamenkovic 2003). ECM is 
essential in tissue architecture and homeostasis, but its functions reach far beyond 
being the passive structural component of tissues, and it is an important mediator of 
cell-cell interactions and cell signalling. The ECM is a reservoir of resting cytokines, 
proteases and growth factors that are liberated from this mesh upon breakdown 
of the matrix proteins (Stamenkovic 2003). The intact ECM mediates signals 
affecting cell survival, and damage to its structure may initiate processes leading 
to cell death. A phenomenon called anoikis-like cell death refers to a process where 
interaction between epithelial cells and ECM is disrupted, a survival signal from 
intact interaction is lost and cellular apoptotic mechanisms are activated (Frisch et 
al. 1994). Attachment of the epithelial cells to the basement membranes seems to 
be of particular importance because disruption of this contact by inactivating the 
integrins promotes apoptosis (Boudreau et al. 1995).
During various physiological and pathophysiological processes the ECM is 
subject to continuous remodelling. MMPs are central players in these processes, 
which include morphogenesis, angiogenesis, growth, wound healing and 
reproduction-associated processes, but also disease processes such as tumour 
;  " '/  '' !""  '
</=	'/ !"" $
and basement membranes are degraded as leukocytes migrate from the circulation 
:!""/'$$@$$@
are together able to digest proteolytically virtually all components of the ECM, 
this matrix-degrading function was traditionally perceived as their main function 
 !""'&;'/'"
important functions of MMPs include mobilizing and activating cytokines and 
17
growth factors from the ECM (Rodriguez et al. 2010) and working as tuners and 
":""/:/'<=
2.1.2. NEUTROPHILS 
{/   > ::' '   ""/ :' 
invading microbial organisms (Marshall 2005). They express pattern recognition 
receptors, such as Toll-like receptors, that recognize conserved molecular patterns 
found on microbes (Hayashi et al. 2003). Recognition of these patterns leads to 
activation of circulating neutrophils to express L-selectins, which recognize adhesion 
molecules and selectins on the activated endothelium, thus facilitating adherence to 
the capillary endothelium (Marshall 2005). Neutrophils are directed to the site of 
injury by fast chemoattractation by CXC chemokines, e.g. interleukin-8 (IL-8), the 
most abundant chemokine in humans. Activation of the chemokine receptors leads 
to migration through the capillary wall towards a chemokine gradient, release of 
intracellular granules and initiation of the respiratory burst. During the migration 
and killing of the microbes neutrophils produce reactive oxygen species and nitrogen 
molecules and release proteolytic enzymes (Marshall 2005). The latter include serine 
proteinases such as elastase, cathepsin G, urokinase-type plasminogen activator and 
myeloperoxidase and MMP-8 and -9 (Owen et al. 1999). These proteinases have the 
potential to cause extensive collateral damage to the surrounding tissues (Marshall 
#='':;;"'
leads to an increase in life-threatening infections (Gallin et al. 1985). 
After phagocytosis and bacterial killing neutrophils undergo self-programmed 
apoptosis and are phagocytosed by macrophages (Savill et al. 1989). Subsequently, 
>!"" "'/:
/"/':'><%{?>=''::"
:'><%`?>=	>!""/<;
=	/'/'<=
@>!""'%{?>	>	>'Q//'
/Q>!""	><=
The decreased neutrophil apoptosis may be detrimental by several mechanisms, 
with continuing release of harmful mediators and subsequent tissue injury. It may 
also lead to impaired resistance to secondary infections. In a recent study, those 
trauma patients with increased polymorphonuclear (PMN) leukocyte apoptosis in 
;'	"":'
(Morrison et al. 2012). 
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2.1.3. MATRIX METALLOPROTEINASE FAMILY
As neutrophils secrete MMP-8 and MMP-9, there is a large group of MMPs released 
from other cell types. %$$@''QQ`
and Lapière in an involuting tail of a metamorphosing tadpole (Gros and Lapière 
1962). Since then, at least 25 members of the MMP family have been discovered (Van 
Lint et al. 2006). MMPs are genetically distinct and structurally related zinc- and 
calcium-dependent endopeptidases (Sternlicht et al. 2001). MMPs have substantial 
overlap in their substrates, and together they are able to digest all components 
of the ECM (Sternlicht et al. 2001). On the basis of their preferred substrate 
''$$@'Q; /'<$$@> >J
-13) degrade interstitial collagen; gelatinases (MMP-2 and -9) degrade denatured 
collagen, gelatin; stromelysins (MMP-3 and -10 and -11) digest ECM components 
and activate other MMPs; matrilysins (MMP-7 and -26) degrade ECM components 
and cell surface molecules; membrane-type MMPs (MMP-14, -15, -16,-17, -24 and 
-25), and others (reviewed in Visse 2003). Neutrophil-derived MMP-8 and -9 are 
described in detail below.
2.1.4. REGULATION OF MATRIX METALLOPROTEINASES 
MMPs are regulated at several levels, namely transcription, activation of the pro-
enzyme and inhibition of the active enzyme. Most cell types do not express MMPs in 
Q/'"//'>!""'';
transcription. MMPs are secreted as inactive zymogens that need to be activated— for 
most MMPs, this occurs extracellularly. The activation involves a “cysteine switch” 
that requires displacing of a sulfhydryl group of a cysteine residue at the catalytic site 
and thus exposing the zinc needed for the catalytic actions (Springman et al. 1990). 
Subsequent autocatalysis or cleavage by other active MMPs leads to formation of the 
active proteinase (reviewed in Visse 2003). MMP activators include serine proteases, 
oxidized glutathione, other MMPs (Visse 2003) and reactive oxygen (Peppin et al. 
J='<`/=	Q!/""
Q>''">"'Q/'Q
to MMPs covalently (Sottrup-Jensen et al. 1989). At the tissue level, MMPs are 
inhibited by non-covalently binding to tissue inhibitors of metalloproteinases 
(TIMPs) (reviewed in Visse 2003). Unbound, MMPs may also undergo spontaneous 
degradation by autocatalysis (Yan et al. 2001). MMPs may avoid inhibition by TIMPs 
by cell membrane localization (Owen et al. 2004), but they can be inhibited also 
on the cell surface. For example, a cell surface receptor RECK (reversion-inducing 
cysteine-rich protein with kazal motifs) is a cell surface MMP inhibitor (Oh et al. 
2001). MMP inhibition is concentration-dependent because TIMPs bind MMPs in 
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a 1:1 molecular ratio. The inhibition by TIMPs as well as plasma proteinases may 
be circumvented by leukocytes locally by creating a plasma-free microenvironment 
where pro-MMP is secreted and activated for facilitating transmigration through 
Q"""Q<'/=%Q''Q/
':;"!"""/:""
exceed the amount of their inhibitors, they have the capacity to cause damage to 
the tissues, especially to the ECM structures. 
2.1.5. MATRIX METALLOPROTEINASE-8 (MMP-8)
Matrix metalloproteinase-8, also known as collagenase-2, belongs to the group 
: ' 	'Q JQ/
''@${/:"@${JQ&
who also sequenced this PMN-secreted form (Hasty et al. 1990). Although MMP-
8 can cleave collagens I, II and III, its preferred substrate is collagen I (Hasty et 
al. 1987), and it is the only PMN-derived proteinase able to digest type I collagen 
(Owen et al. 1999). 
Traditionally, it was believed that MMP-8 is not synthesized de novo by mature 
PMN because the synthesis occurs predominantly at the myelocyte stage of maturing 
neutrophils (Cowland et al. 1999). However, also mature and activated neutrophils 
have been found to express MMP-8 mRNA (Cole et al. 1995). The latent 95 kDa 
"''/:@${/'<$/=
Human peripheral blood neutrophils contain about 60 ng MMP-8/ 106 cells and 
they release small amounts when unstimulated (Owen et al. 2004). When the cells 
';Q!"""/Q/#>:
enzyme as a soluble proteinase (Owen et al. 2004). MMP-8 is also located bound 
to the cell membrane of activated neutrophils, where it is proteolytically active and 
resistant to tissue inhibitors (Owen et al. 2004). When not bound to the membranes, 
the half-life of soluble MMP-8 in 37°C is 7.5 hours (Owen et al. 2004). MMP-8 
is synthetized also by various other cell types, examples of which are provided in 
%Q%//Q>!""'/Q'
involved in the regulation are shown in Table 1.
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Table 1. Cell types expressing MMP-8 and MMP-9, regulators of synthesis, substances involved in enzyme 
activation and enzyme substrates.
Cell type (reference) Regulators of synthesis Enzyme  
activated by
Substrates cleaved
MMP-8 -Neutrophil granulocytes       
(Hasty et al. 1986)
-Chondrocytes                              
(Cole et al. 1996)
-Rheumatoid synovial 
	

(Hanemaaijer et al. 1997)
-Activated macrophages      
(Herman et al. 2001)
-Smooth muscle cells                
(Herman et al. 2001)
-Bronchial epithelial cells     
(Prikk et al.  2001)
-Endothelial cells                
(Hanemaaijer et al. 1997)
-Odontoblasts                          
(Palosaari et al. 2000)
-Lymphocytes                          
(Lindberg et al. 2006)
-Plasma cells                          
(Wahlgren et al. 2001)




(Hanemaaijer et al. 1997)




(Chubinskaya et al. 1996)




(Wahlgren et al. 2001)




(Palosaari et al. 2000)
-Trypsin,
chymotrypsin,
pancreatic 
kallikrein, 
cathepsin G 
(Knäuper et al. 
1990)
-MMP-3 
(Knäuper et al. 
1993)
-MMP-7 
Balbin et al. 1998)
-Tryptase 
(Gruber et al. 
1988)
-Reactive oxygen 
species 
(Saari et al. 1992, 
Claesson et al. 
1996)
-Peroxynitrite 
(Okamoto et al. 
2001)
-Collagen I, II, III  
(Hasty et al. 1987)
-Bradykinin, angiotensin I, 
substance P 
(Diekmann et al. 1994)
		

antichymotrypsin     
(Michaelis et al. 1990, 
Desrochers et al. 1992)
!"

(Sottrup-Jensen et al. 1989)
#$

(Quintero et al. 2010)
-IL-10 
(Garcia-Prieto et al. 2010)
-Chemokines 
(Van den Steen et al. 2003)
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The table gives examples of the origin, regulation of synthesis and activity as well as some substrates 
of MMP-8 and MMP-9. Different cell types respond to different regulators of synthesis, but for 
simplicity these differences are not indicated in the table. MMP= matrix metalloproteinase; TNF-α= 
tumour necrosis factor-α ; IL= interleukin; TGF-β= transforming growth factor-β; MIP-1α= macrophage 
inflammatory protein; LPS= lipopolysaccharide
Like other MMPs, MMP-8 is secreted as an inactive pro-enzyme that needs to be 
activated. Examples of substances involved in MMP-8 activation are presented 
in Table 1. The enzyme is inactivated by EDTA, cysteine and reduced glutathione 
and also by omitting calcium (Lazarus et al. 1968). The physiological functions of 
MMP-8 are not restricted to ECM collagen degradation, and considering the variety 
:!"""/Q"
Cell type (reference) Regulators of synthesis Enzyme  
activated by
Substrates cleaved
MMP-9 -Neutrophil granulocytes 
(Murphy et al. 1989)
-Mononuclear phagocytes 
(Welgus et al. 1990)
-Eosinophils  
(Ohno et al. 1997)
-Macrophages  
(Hibbs et al. 1987)
-T-lymphocytes  
(Leppert et al. 1996)
-B-lymphocytes  
(Trocmé et al. 1998)
-NK cells  
(Kitson et al. 1998)
- Fibroblasts  
(Wilhelm et al. 1989)
-Vascular endothelial cells 
(Renckers et al. 2006)
-Smooth muscle cells 
(Renckers et al. 2006)
-Platelets (Fernandez-
Patron et al. 1999)
-Mesothelial cells 
(Marshall et al. 1993)
-Neurons, astrocytes, 
oligodendrocytes, 
microglia (Conant et al. 
1999, Rivera et al. 2002, 
Rosenberg 2001)
- Amnion epithelial cells 
(Lehtovirta et al. 1994)



(Sarén et al. 
1996, Unemori et al. 
1991)



 
(Sarén et al. 1996, 
Unemori 1991)
IL-2  
(Kitson et al. 1998)




 
(Wahl et al. 1993)


$%
 
(Welgus et al. 1990)


&
(Mostafa Mtairag 
et al. 2001)


'

(Shapiro 
et al. 1990, Sarén et al. 
1996, Leppert et al. 1996)


*
 
(Lacraz et al. 1992)


"	+
 
(Aljada et al. 2001)
-Nitric oxide (Gu 
et al. 2002)
-Reactive nitrogen 
species (Okamoto 
et al. 2001)
-Reactive oxygen 
species (Peppin 
et al. 1986)
-Trypsin (Sorsa et 
al. 1997)
-Stromelysin-1, 
MMP-2 (Ogata et 
al. 1992, Fridman 
et al. 1995)
-MMP-7 (Balbin et 
al. 1998)
-Plasmin 
(Baramova et al. 
1997, Makowski 
et al. 1998)
-PMN elastase 
(Ferry et al. 1997)
-Bacterial 
products (Oggioni 
et al. 2003)
- Gelatin, type IV collagen
-Type V collagen  
(Murphy et al. 1977)
- Collagen VII, X, elastin 
(Senior et al. 1991)
-Laminin (Owen et al. 1999)
-Aggrecan  
(Fosang et al. 1992)

(Scönbeck et al. 
1998, Ito et al. 1996)
-IL-8  
(Van den Steen et al. 2000)
-Other chemokines  
(Van den Steen et al. 2003)

.4445
 
(Gearing et al. 1994)


(Yu et al. 2000)
-IL-2 receptor  
(Sheu et al. 2001)

	44
:	

(Desrocher et al. 1992, Liu 
et al. 2000)
-Big endothelin (Fernández-
Patron et al. 2001)
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activate nuclear transcription factor nuclear factor kappaB (NFkB) directly, thus 
>!"""'''
and chemokine production. Examples of MMP-8 substrates are presented in Table 
1. It can cleave vasoactive substances, inactivate proteolytically serine protease 
inhibitors and activate and inactivate chemokines. MMP-8 is considered important 
in neutrophil chemotaxis (Tester et al. 2007). Based on studies on mice genetically 
'$$@>J'''/!""";':
"/'''/"/:/:!""
but also a delayed clearance of the neutrophils and therefore delayed healing. This 
may be due to decreased neutrophil apoptosis (García-Prieto et al. 2010, Balbin et al. 
2003). For example, mice genetically lacking MMP-8 have delayed wound healing 
!""''QQ/''/"/
of neutrophils due to delayed neutrophil apoptosis (Gutiérrez-Fernández et al. 
2007). The delayed accumulation of neutrophils in the absence of MMP-8 suggests 
"/:'
'"
Delayed wound healing has been described also in rats overexpressing MMP-8 in 
QQ;:$$@>J''"Q'"/
of myeloperoxidase at later stages of healing, which in turn suggests that MMP-8 
may have a role in the dampening of neutrophil response. A decreased collagen 
content and impaired tensile strength was seen in the wounds, suggesting that high 
tissue levels of MMP-8 delay proper healing (Danielsen et al. 2011). 
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rheumatoid arthritis (Matsuki et al. 1996), osteoarthritis (Cole et al. 1995), cystic 
Q<@*=<#='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(Nwomeh et al. 1999), and atherosclerosis (Pradhan-Palikhe et al. 2010). It has 
also been shown to promote tumour invasion and metastasis in several studies 
(reviewed in Van Lint et al. 2006). 
2.1.6. MATRIX METALLOPROTEINASE-9 (MMP-9)
MMP-9 is another metalloproteinase secreted by neutrophils (Murphy et al. 1989). 
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the earlier literature, MMP-9 has been referred to as type IV collagenase, type V 
collagenase, 92-kDa collagenase and gelatinase B. Like MMP-8, it is mostly synthetized 
in maturing neutrophils, but synthesis is also possible in mature neutrophils 
(Nagaoka et al. 2000). It is stored in tertiary granules of PMN (Borregaard et al. 
2001), and almost immediate degranulation occurs after neutrophil activation with 
IL-8 (Masure et al. 1991, Pugin et al. 1999a), lipopolysaccharide (LPS) stimulation 
23
(Pugin et al. 1999a= %{?> `>? </' ' "/ :'=
phytohaemagglutinin (Pugin et al. 1999a) or tissue plasminogen activator (Cuadrado 
et al. 2008). It is also expressed in various other cell types (Table 1). In contrast 
to neutrophils, MMP-9 is not stored in most of the other cells and its constitutive 
expression is limited. Synthesis is upregulated at least via nuclear transcription 
factor AP-1 (Speidl et al. 2004). The LPS-induced expression and activity is further 
Q''"/""'QQ;>'
mediated mechanism (Speidl et al. 2004). In vivo, MMP-9 is upregulated very 
fast after LPS challenge (Pugin et al. 1999a, Paemen et al. 1997). The synthesis is 
/Q>!""''//:
TIMP-1 in many cell types. Glucocorticoids suppress MMP synthesis; for example, 
hydrocortisone suppresses plasma MMP-9 levels of healthy subjects within 1 hour of 
a single intravenous dose of 100 mg (Aljada et al. 2001). Dexamethasone does not 
block the degranulation of MMP-9 from neutrophils (Pugin et al. 1999a), indicating 
that the suppression occurs at the level of transcription. 
MMP-9 is secreted in several forms: as a 92 kDa pro-enzyme, as a 130 kDa 
complex with neutrophil gelatinase-associated lipocalin (NGAL) (Yan et al. 2001) 
and as a 200 kDa homodimer (Opdenakker et al. 2001b). NGAL is thought to 
protect MMP-9 from degradation and to help preserve its enzymatic activity (Yan 
et al. 2001). Functionally, MMP-9 is a gelatinase and a type IV collagenase that 
is able to cleave collagen after an initial cleavage by collagenases, and native type 
IV collagen, which is a major component in basement membranes. It also digests 
various other components of the ECM (Table 1). Like other MMPs, MMP-9 needs 
to be activated to exert its functions. Activators include serine proteases, reactive 
oxygen and nitrogen species and other MMPs (Table 1). Also certain virulent 
strains of Streptococcus pneumoniae produce proteases that are able to cleave 
and thus activate MMP-9 (Oggioni et al. 2003). MMP-9 is active at physiological 
pH and temperature (Fasciglione et al. 2000). At the tissue level, MMP-9 is rapidly 
inactivated by TIMPs and proteolytic self-degradation (Yan et al. 2001).
$$@>"//::/';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It facilitates neutrophil transmigration across basement membranes in response 
to chemoattractant stimulation (Delclaux et al. 1996). It creates positive and 
;:Q'''';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to the biologically active form (Schönbeck et al. 1998) and also degrades active 
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/>J  " :/
neutrophil-activating chemokine, to a 10-fold more potent form (Van den Steen et 
=''"<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and inactivates IL-2 receptor, resulting in inhibition of T-cell proliferation (Sheu 
et al. 2001). It may also potentiate the function of other proteinases because it is 
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elastase (Liu et al. 2000). By cleaving endothelin to its vasoactive form, endothelin-1, 
it stimulates its own release from neutrophils, creating a positive feedback loop, 
and promotes enhanced adhesion (Fernandez-Patron et al. 2001). Finally, MMP-9 
"'Q/":!""Q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impaired neutrophil apoptosis in an experimental peritonitis model (Kolazkowska 
et al. 2009).
2.1.7. MATRIX METALLOPROTEINASE-7 (MMP-7)
MMP-7, also known as matrilysin or PUMP-1, is the smallest and structurally 
simplest of the MMPs, with a molecular weight of 28 kDa (Wilson et al. 1996). 
It is expressed constitutively by epithelial cells (Wilson et al. 1996) such as 
glandular epithelial cells of the mammary gland, pancreas, parotid gland, liver 
and peribronchial glands (Saarialho-Kere et al. 1995). MMP-7 is also produced by 
monocytes (Busiek et al. 1992). 
It can cleave laminin and entactin (Wilson et al. 1996, Sires et al. 1993) and 
various other ECM components (Imai et al. 1995), insulin, transferrin, serpins (Sires 
et al. 1994), pro-uPa and uPa (Wilson et al. 1996). MMP-7 activates both MMP-8 
(Balbin et al. 1998) and MMP-9 (Imai et al. 1995). It seems important in cleaving 
'""Q/Q:"'""QQ/%{?>
precursor to its active, soluble form (Gearing et al. 1994). Another membrane-
bound protein, Fas-ligand (FasL), is cleaved into soluble FasL by MMP-7 to promote 
apoptosis by binding to its receptor on epithelial cells (Powell et al. 1999). In the 
intestine, MMP-7 is found in the Paneth cells in the crypts of small intestine (Wilson 
#=';Q'"'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Q'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>!""
cytokines (López-Boado et al. 2000). MMP-7 is important in epithelial repair and 
migration; for example, in airway injury the epithelial cells cannot migrate in the 
absence of MMP-7 (Dunsmore et al. 1998). Similar importance of MMP-7 in cell 
migration is seen in gastric epithelial cells in the presence of Helicobacter pylori 
:'<Q=	"/!/:"
the interstitium to the alveoli is detected in mice lacking MMP-7 due to the absence 
of MMP-7-driven shedding of syndecan-1 from the cell surfaces (Li et al. 2002).
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2.1.8. TISSUE INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) 
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%	$@';%	$@>:/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and its ability to inhibit collagenases was recognized (Woolley et al. 1975). Four 
%	$@;Q/"%	$@"Q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inhibit MMPs by forming non-covalent bonds with 1:1 stoichiometry (reviewed in 
Lambert et al. 2004). TIMP-1 and TIMP-2 inhibit many MMPs, but TIMP-2 has a 
'::$$@><&=%	$@>Q$$@>"
effectively than TIMP-1 (Howard et al. 1991), but TIMP-1 prefers to form complexes 
with the pro-form of MMP-9 (Wilhelm et al. 1989). TIMP-1 is expressed in a variety of 
'':/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induced by several growth factors (reviewed in Lambert et al 2004) and cytokines 
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al. 1992), IL-10 (Mostafa Mtairag et al. 2001) and bacterial LPS (Pagenstecher et 
al. 2000). Catecholamines upregulate its expression (Speidl et al. 2004). 
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is in part coordinately regulated with MMP expression, but certain regulators 
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of collagenases and increases TIMP-1 production, at least in certain cell types 
(Overall et al. 1994). TIMP-1 is inactivated by neutrophil elastase (Okada et al. 
1988), myeloperoxidase (Wang et al. 2007) and peroxynitrite, a reactive nitrogen 
'<?=:"//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Functionally, TIMP-1 has various effects on neutrophils. It activates neutrophils, 
potentiates their respiratory burst, protects them from apoptosis and inhibits their 
transmigration across basement membranes (Delclaux et al. 1996, Chromek et al. 
2004). TIMP-1 protects certain other cell types from apoptosis in a mechanism 
independent of MMP inhibition (Guedez et al. 1998). 
2.2. MMP- 8, MMP-9 AND TIMP-1 IN SEVERE INFECTION  
AND SEPSIS
2.2.1 SEVERE INFECTION
Altered levels of MMP-8 and -9 have been shown in association with severe 
:';Q>>!"":/''
studies are few and small, with the exception of pulmonary infections, which are 
described in association with acute lung injury below.
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2.2.1.1. Meningitis
Neisseria meningitidis can induce MMP-8 and it is in a key role in the associated 
permeability changes in the cerebral microvasculature by cleaving the tight 
intercellular junction protein occludin (Schubert-Unkmeir et al. 2010). Also MMP-
9 induces the increased permeability and breakdown of the blood-brain barrier 
during experimental bacterial meningitis (Paul et al. 1998). The breakdown 
and permeability changes and subsequent elevated intracranial pressure can be 
inhibited by an MMP inhibitor (Paul et al. 1998). Thus, MMPs -8 and -9 may have 
pathophysiological relevance in bacterial meningitis. Experimental infection with 
intracisternal Streptococcus pneumoniae causes increased synthesis of MMPs -3, 
-7, -8 and -9 in the brain, and by using a broad spectrum MMP inhibitor neuronal 
damage could be prevented (Leib et al. 2000). In another study, a broad spectrum 
MMP inhibitor diminished cortical damage and hippocampal apoptosis as well as 
clinical symptoms, mortality and post-infection learning disturbancies. Importantly, 
these effects were visible also with an inhibitor administered 18 hours post-infection 
:Q'/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et al. 2001). However, the inhibitor used in these studies inhibits also TACE, an 
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/:'Q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as a powerful MMP inducer (Leib et al. 2001). The same applies to doxycycline, which 
was administered 18 hours post-infection to rats with experimental pneumococcal 
meningitis as an adjuvant therapy with ceftriaxone. With doxycycline mortality, 
"Q'/'in 
vitro antagonism of doxycycline and ceftriaxone demonstrated in the same study 
(Meli et al. 2006). The cellular origin of MMP-8 in bacterial meningitis has been 
suggested to be predominantly other cells than neutrophils (Lindberg et al. 2006). 
In clinical studies, elevated levels of MMP-9 (Paul et al. 1998, Leppert et al. 2000, 
Leib et al. 2000), MMP-8 and TIMP-1 (Leppert et al. 2000) are present in the 
'Q!/:Q'"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an association of high MMP-9 levels with neurological sequelae, but the study was 
methologically compromised. 
2.2.1.2. Peritonitis
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" "/   '' "  : $$@>  Q
described (Kolaczkowska 2008). MMP-9 is initially produced by mast cells and 
"'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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9 release with a plateau at 2-8 hours (Kolaczkowska et al. 2008). MMP-9 is also 
produced by peritoneal mesothelial cells (Marshall et al. 1993). MMP-9 seems to 
be especially important in neutrophil transmigration into the peritoneal cavity 
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intraperitoneal Escherichia coli administration. However, in the same study in the 
distant organs the neutrophils were more abundant in knock-out mice than in the 
><%='	/$$@>>'"'"
bacterial clearance and more severe distant organ damage than the WT controls 
(Renckers et al. 2006).This suggests a protective role of MMP-9 in peritonitis. 
Evidence of MMP involvement in human peritonitis comes from studies on patients 
on chronic ambulatory peritoneal dialysis (CAPD). MMP-9 levels and activity are 
'!/:@>':'
compared with non-infected CAPD patients, and then diminishing at the recovery 
phase at 15-30 days after onset. A simultaneous increase in TIMP-1 levels has also 
been detected (Fukudome et al. 2001). Here, the detection of MMP-9 in the infected 
compartment has led to development of diagnostic tools. A MMP-9 antibody-based 
rapid test kit has proven to detect bacterial peritonitis in peritoneal dialysis patients 
;<=''<J#=<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diagnostics, it may have pathophysiological importance, because at least experimental 
studies suggest that MMP-9 present in intestinal anastomoses contributes to the 
weakening of anastomotic strength on the 3rd post-surgical day. Moreover, the 
anastomotic strength can be increased by using an MMP inhibitor (Syk et al. 2001, 
de Hingh et al. 2002). An evident increase in the MMP-9 content of anastomotic 
regions was seen on the 3rd postoperative day when the animals were operated on 
under induced peritonitis conditions and they had a simultaneous weakening of 
anastomotic strength compared with controls operated on without peritonitis (de 
Hingh et al. 2003). This association was, however, transient and limited. 
2.2.1.3. Other infections
MMP-8 is elevated in amniotic infection and may be relevant in preterm rupture 
of fetal membranes (Maymon et al. 1999).
2.2.2. SEPSIS AND SEPTIC SHOCK
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response in an extremely complex manner. MMPs play a role in almost all stages 
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cascades associated with SIRS are shown and the possible stages for MMP 
involvement are indicated. Figure 2 illustrates some of the postulated roles of MMPs 
'!""
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Figure 2. Localized inﬂammation. Bacteria have invaded the tissue, and bacterial components 
initiate the innate immune response. Chemokines and cytokines have promoted leukocyte and 
endothelial activation. The various stages with MMP-7, -8 and -9 involvement are indicated with 
letters A-H. A) Activated neutrophils attach to the endothelial surface and release granular 
contents including MMPs. They migrate through the capillary wall towards a chemokine gradient. 
Basement membrane and ECM components are digested by proteinases, leading to increased 
permeability and tissue damage. B) MMPs released by neutrophils, macrophages and resident 
cells digest the ECM. Loss of cell-ECM contact causes anoikis-like cell death. ECM fragments also 
work as alarmins. Fragmented ECM facilitates cell invasion, but possibly also bacterial spread. C) 
MMPs activate IL-8 to a more potent chemokine and process other chemokines. D) They activate 
IL-1β, but also degrade the mature cytokine. Cytokines upregulate MMP expression in cells. By 
degrading the ECM structure, MMPs liberate resting cytokines and growth factors harboured 
in the matrix. E) MMPs shed membrane-bound TNF-α to a soluble biologically active cytokine, 
which upregulates also MMP expression and inhibits neutrophil apoptosis. F) MMPs may directly 
activate nuclear factor Kappa B promoting the expression of pro-inﬂammatory cytokines and 
MMPs. G) MMP-7 sheds Fas ligand, which may then attach to its receptor and promote epithelial 
cell apoptosis. H) MMPs are released into the circulation. In sepsis, neutrophils degranulate in 
an uncontrolled manner. This may promote circulatory changes and changes in coagulation and 
cause tissue damage.
Experimental studies investigating MMP-8 and -9 levels in different sepsis models 
are summarized in Table 2. In general, sepsis is associated with increased local and 
systemic MMP levels, and the synthesis of the enzymes is upregulated. In several 
studies, mortality is decreased ( Maitra et al. 2003, Hu et al. 2005, Steinberg et 
al. 2003, Vandenbroucke et al. 2012, Solan et al. 2012), and organ damage can be 
prevented or alleviated by using an MMP inhibitor (Maitra et al. 2003, Steinberg 
et al. 2003, Steinberg et al. 2005). Because the available MMP inhibitors are non-
selective regarding the inhibited MMP and some are also TACE inhibitors, it is 
not possible to differentiate the roles of individual MMPs based on these studies. 
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damage in sepsis models compared with their WT counterparts (Van Lint et al. 2005, 
Vandenbroucke et al. 2012, Solan et al. 2012). They express less chemokines (Van 
#=>!""'<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Although the chemokine levels were lower and the animals had less neutrophil 
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et al. 2012). These results suggest a deleterious role for MMP-8 in sepsis. The 
results from MMP-9 knock-out models are controversial. Dubois et al. (2002) found 
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impaired clearance of pathogens (Renckers et al. 2006). It should be noted that 
the sepsis models were different; the model in the latter study resembled human 
sepsis more closely. 
In healthy volunteers, infusion of lipopolysaccharide causes a rapid upregulation 
of proMMP-9 in the circulation, peaking as early as 1.5-3 hours (Pugin et al. 1999a, 
Albert et al. 2003). This initial upregulation is probably due to immediate release 
from activated neutrophils because in other cell types MMP-9 is released slower 
in response to LPS stimulation in vitro and is probably due to increased synthesis 
(Pugin et al. 1999a). In a small study of septic patients, plasma MMP-9 was increased 
/:/Q/"<$=%	$@>
1 was elevated throughout the study period, days 1-5 of severe sepsis in the same 
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2. REVIEW OF THE LITERATURE
The clinical studies investigating MMP-8 or -9 in septic patients are few and small. 
The studies are summarized in Table 3. Three studies report elevated MMP-9 in 
patients relative to controls. One study found no difference, and in one study MMP 
levels were lower in patients. In one study, no difference existed between septic 
and non-septic critically ill patients. Nakamura et al. (1998) reported higher levels 
of MMP-9 in non-survivors; whereas in two studies there were no differences in 
MMP-9 levels and in one study MMP-9 levels were higher in survivors (Lorente et 
al. 2009). Elevated MMP-8 expression was associated with decreased survival in 
a retrospective study (Solan et al. 2012), while no difference was found in another 
small study (Gäddnäs et al. 2010).
Interestingly, TIMP-1 levels were associated with increased mortality in two 
studies (Hoffman et al. 2006, Lorente et al. 2009). 
2.2.3. ORGAN DYSFUNCTION
Increased endothelial and epithelial basement membrane permeability, neutrophil 
accumulation and damage to tissue architecture are all features of sepsis-associated 
organ dysfunction (Fry 2012). MMPs have been suggested to be involved in these 
processes because of their ability to process ECM components and to tune and 
amplify immune reactions. In a mouse model of multiple organ dysfunction, initiated 
by zymosan-induced peritonitis, expression of MMP-9 mRNA was detected in 
several distant organs and active enzyme was detectable especially in the spleen and 
the liver (Volman et al. 2004). This upregulation was visible at 5-12 days after the 
/Q//'''"
of organ dysfunction.  A similar enhanced MMP-9 expression and corresponding 
upregulation of MMP-9 protein in several distant organs was seen in LPS-induced 
endotoxaemia in mice. Concomitant upregulation of the TIMP-1 gene was also 
noted (Pagenstecher et al. 2000). In a moderate-sized multi-centre study on septic 
patients, Lorente et al. (2009) found that MMP-9 and TIMP-1 correlated positively 
with SOFA, lactate and markers of coagulopathy. Another study reported increased 
$$@>;Q!/>'$<`
et al. 2010). In addition, MMP-8 mRNA was associated with severity of organ failure 
in a recent small retrospective study on septic children (Solan et al. 2012). MMP-
8 and -9 are reviewed below in the context of sepsis-induced organ dysfunction. 
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2.2.3.1. Kidney
In a study by Pagenstecher et al (2000) the localisation of increased gelatinolytic 
activity in the kidney was seen predominantly in the walls of small vessels. The role of 
MMP-8 and -9 in human acute kidney injury has been poorly investigated. Recently, 
;/"$$@>J:/Q;Q/>''Q"
'/!//'>''>'	
paediatric patients (Basu et al. 2011). 
2.2.3.2. Coagulation  
No clinical studies investigating the role of MMP-8 or -9 in sepsis-associated 
disseminated intravascular coagulation exist. However, MMP-8 and -9 have 
/:/':::'/Q'
MMP-9 seems to act both in favour and against clot formation. Neutrophils 
degranulate and release MMP-8, MMP-9 and TIMP-2 in response to stimulation 
with recombinant tissue plasminogen activator (Cuadrado et al. 2008). MMP-8 
cleaves tissue factor pathway inhibitor (TFPI), the primary inhibitor of the tissue 
factor pathway of coagulation, in vitro, leading to a diminished inhibitory action 
of TFPI on factor Xa (Cunningham et al. 2002). MMP-7 and -9 are also capable 
of cleaving TFPI (Belaaouaij et al. 2000). Human platelets secrete MMP-9 in 
response to thrombin stimulation, and MMP-9 inhibits thrombin-induced platelet-
aggregation (Fernandez-Patron et al. 1999). The synthesis of MMP-9 is upregulated 
Q/"';<&/=$$@>QQ
activated by a plasmin-mediated pathway (Baramova et al. 1997, Makowski et 
J=$$@>'/Q'>Q<^=$$@>J
Q';Q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"/"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=	'/$$@>J>'"'%"'
''/"'>/"':@"/
(Vandenbroucke et al. 2012). 
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Figure 3. Suggested roles for MMPs in coagulation and ﬁbrinolysis. 1. Various cells express tissue 
factor, which upon tissue damage activates the extrinsic coagulation pathway, leading to the activation 
of factors VII and X. This is inhibited by tissue factor pathway inhibitor (TFPI). Uninhibited, this leads 
to activation of prothrombin to thrombin, which converts ﬁbrinogen to ﬁbrin. 2. AT III is a major 
physiological anticoagulant, that may be inactivated by elastase. MMP-8 and -9 inactivate proteinase 
inhibitor, which is a potent inhibitor of elastase. This may lead to potentiation of AT III degradation by 
elastase. 3. Both MMP-8 and MMP-9 inactivate TFPI by cleavage and may thus contribute to activation 
of the extrinsic pathway. 4. MMP-9 cleaves big endothelin to vasoactive endothelin, thus potentially 
contributing to local vasoconstriction. 5&6. Thrombin stimulates platelets to release MMP-9, which acts 
on platelet cell membrane to decrease aggregation. 7. Plasmin activates MMP-8 and MMP-9. They may 
bind to ﬁbrin to inactivate it by cleavage, thus decreasing clot formation.
2.2.3.3. Brain 
Septic encephalopathy, i.e delirium, is usually an early feature of sepsis-associated 
organ dysfunction. The pathophysiological mechanisms are not well known, but one 
of the suggested mechanisms involves increased permeability of the blood-brain 
Q<^^^=/Q/!/:>!"""<;
Ebersodlt et al. 2007). MMPs may well play a role in BBB disruption, because MMP-9 
cleaves BBB effectively in experimental infection and also in ischaemia/reperfusion-
associated SIRS (Paul et al. 1998, Rosenberg et al. 1996). Even distant organ damage 
may trigger this permeability change, at least experimentally. Namely, peripheral 
thermal injury is associated with increased MMP-9 mRNA in brain tissue, coinciding 
with increased BBB permeability (Swann et al. 2007). In addition to the BBB, MMPs 
may alter the permeability of other important barriers. Recently, the important role 
:$$@>J/Q>'Q!/Q<Q>?Q=
in sepsis and renal ischaemia-reperfusion-induced SIRS was demonstrated by 
Vandenbroucke et al. (2012). Blood-CSF barrier, formed by the chorioid plexus, 
was protected from disruption in MMP-8 -/- mice and by using an MMP inhibitor. 
''/''!""
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(Vandenbroucke et al. 2012). The blood-CNS barrier has been described as the 
immune monitor of the brain, which in turn exerts immunomodulatory functions 
on the whole body. By affecting the patency of this barrier, MMP-8 may be involved 
/:"'!""<Q/'Q
et al. 2007). However, MMPs may also exert important physiological functions in 
neuronal maintenance and reparative processes.  In experimental studies, MMP-9 
seems to affect neuronal plasticity and promote memory and learning (Nagy et al. 
2006, Meighan et al. 2006). Interestingly, a recent study found that in critically 
ill patients lower plasma MMP-9 levels were associated with increased risk for 
delirium, but the mechanism remains unclear (Girard et al. 2012).
2.2.3.4. Liver
A potential role of MMP-8 in hepatic tissue damage was suggested by Van Lint et 
<#=:/"'''$$@>J
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/!/
the liver. This was thought to be due to lack of chemokine production in knock-out 
mice. On the other hand, lack of MMP-9 seemed to lead to more severe liver damage 
in an experimental mouse peritonitis model (Renckers et al. 2006).
2.2.3.5. Circulation
In endotoxaemic rats, vascular hyporeactivity to vasoconstrictors can be attenuated 
by administering doxycycline, an MMP inhibitor (Lalu et al. 2006). This seems to 
be independent or at least a downstream mechanism of the iNOS (inducible nitrix 
oxide synthase)-mediated pathway (Cena et al. 2010). In septic rat myocardium, 
cardiomyocytes express increased amounts of MMP-9 (Cuenca et al. 2006). It 
is well established that in the non-septic failing heart ECM remodelling takes 
place and MMPs are involved in these processes (reviewed by Tsuruda 2004). 
In a recent experimental model of acute pulmonary embolism an upregulation 
of MMP-9 was seen after embolism. By using doxycycline this upregulation and 
concomitant increase in pulmonary vascular resistance index and mean pulmonary 
artery pressure could be diminished (Fortuna et al. 2007).
2.3. MMP-8, MMP-9 AND TIMP-1 IN ACUTE LUNG INJURY
MMP-8 and -9 participate in the pathophysiology of various acute and chronic lung 
diseases such as MMP-9 in interstitial pneumonias (Suga et al. 2000), tuberculosis 
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(Chang et al. 1996), MMP-8 in bronchiectasis (Sepper et al. 1995) and MMP-8 and -9 
''Q<=''Q/';/"<@=
(Segura-Valdez et al. 2000) and asthma (Vignola et al. 1998, Prikk et al. 2002). Most 
:'''/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In acute infection, such as community-acquired pneumonia, MMP-9 activity and 
concentration in plasma are elevated (Yang et al. 2005). Similar results of elevated 
MMP-8 and -9 in mini-BAL (broncho-alveolar lavage) (Hartog et al. 2003, El-
Solh et al. 2010) and plasma (Hartog et al. 2003) have been reported in patients 
with hospital-acquired pneumonia. In these patients, an association of MMPs with 
clinical severity of the disease was found (Hartog et al. 2003, El-Solh et al. 2010). 
Infection by highly pathogenic strains of Pseudomonas aeruginosa was associated 
with higher MMP-8 and -9 levels, and a high MMP-9/TIMP-1 ratio was associated 
with increased alveolo-capillary leakage and mortality (El-Solh et al. 2010). Elevated 
$$@>J>^!/:/';>'/"<@=
may differentiate true VAP from non-VAP (Wilkinson et al. 2012).
2.3.1. ALI/ARDS DEFINITION AND PATHOPHYSIOLOGY
Acute respiratory failure (ARF) is a common reason for intensive care admissions 
(Vincent et al. 2002, Linko et al. 2009), and especially its most severe forms, acute 
lung injury (ALI) and acute respiratory distress syndrome (ARDS), bear high 
mortality (Vincent et al. 2002, Linko et al. 2009). While ARF lacks a generally 
''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Consensus Conference criteria which include acute onset of hypoxaemia (ratio of 
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severity categories of ARDS. It recognizes certain underlying diseases as risk factors 
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is a pathophysiologically central feature in the acute phase of lung injury (Ware 
et al. 2000). Accumulation of neutrophils and platelets, activation of coagulation 
pathways and altered permeability in the endothelial wall and epithelial structures 
'<$=?/"';:""/
response via Toll-like receptor activation plays an essential role in ALI (Matthay 
et al. 2012). 
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2.3.2 THE ECM IN THE LUNG
The ECM in the lung consists of type I collagen, which is responsible for the tensile 
strength of the lung tissue and is highly resistant to proteolytic enzymes. Elastin 
provides distensibility of tissue. Endothelial and epithelial basement membranes 
contain type IV collagen, and the alveolar wall mainly consists of type III collagen 
(Elkington et al. 2005). MMP-8 and MMP-9 together can cleave all of these ECM 
'/;    ;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tempting to believe that they may participate in ALI pathogenesis. In experimental 
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models of lung injury, summarized in Table 4. Studies using different models of 
injury and animals treated with MMP inhibitors show that by using inhibitors 
/''/"///:>!"""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tissue damage and permeability changes can almost always be attenuated (Table 5). 
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and therefore, their independent roles can not be fully elucidated based on these 
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their independent roles and are shown in Table 6.
2.3.3 MMP-8 AND ACUTE LUNG INJURY
MMP-8 is detectable in BAL of healthy volunteers (O´Kane et al. 2009). Only a few 
clinical studies have assessed MMP-8 levels in ALI, and no studies report systemic 
MMP-8 levels. In ALI MMP-8 seems to be elevated in BAL or tracheal aspirates. 
The source of MMP-8 in lung injury seems to be predominantly neutrophils. 
MMP-8 in tracheal aspirates of paediatric ARDS correlates strongly with other 
neutrophil proteinases such as human neutrophil elastase and myeloperoxidase 
(Kong et al. 2011). However, different cell types may be responsible for the MMP-8 
production depending on the model used. In one experimental study, the presence 
of a lower molecular weight form consistent with mesenchymal MMP-8 was also 
'<;=/QQ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Pieto et al. 2010). 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
MMP-8 knock-out mice seem to have more neutrophil accumulation, permeability 
changes and capillary injury than WT mice (see Table 6). Neutrophil apoptosis is 
''>/"	>$	@>"
levels. In one study using three different mechanisms of injury, MMP-8 -/- mice had 
higher mortality in all groups (Quintero et al. 2010), whereas another study found 
no difference in survival, although the initial lung injury was more severe in the 
MMP-8 -/- mice (González-Lopéz 2012). In a bleomycin model of lung injury, knock-
/'!""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
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in the later stages (García-Prieto et al. 2010). Interestingly, in at least one study 
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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that loss of one enzyme may be compensated by another (García-Prieto et al. 2010). 
In humans, at least locally in the lung, MMP levels tend to be elevated in 
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a study of 28 patients with ALI/ARDS, elevated levels of MMP-8 were detected in 
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reported increased MMP-8 levels in ARDS patients, with unchanged concentrations 
between days 0 and 4 of the disease. High MMP-8 levels in tracheal aspirate samples 
were present at 24 (Kong et al. 2009) and 48 hours (Kong et al. 2011) after onset 
of ARDS in paediatric patients, and MMP-8 levels decreased markedly between 
days 2 and 6 of disease (Kong et al. 2011). 
/$$@>J;;^!/:	
::"
'"/Q':;'{':$$@>
8 was found with any outcome measures, disease severity or oxygenation disorder 
(Fligiel et al. 2006). On the contrary, high tracheal aspirate MMP-8 in paediatric 
ARDS patients predicted need for longer mechanical ventilation independently 
(Kong et al. 2011).
Table 4. Experimental studies examining MMP levels in lung injury. 
Author, year Animals Model of injury Measures Results Other
Gibbs  
et al. 1999
Rats Tracheally instilled IgA 
immune complexes, LPS
BAL MMP-9 MMP-9 elevated in BAL 
after IgA and LPS
Injury was partly 
inhibited by TIMP-2
Gushima  
et al. 2001
Pigs Hyperoxia BAL and tissue 
MMP-2 and -9, 
correlation with 
oxygenation, number 
of neutrophils and 
wet-to-dry ratio
MMP-2 and -9 
increase after 72hours, 
MMP-9 localized 
in macrophages, 
neutrophils and 
alveolar lining 
epithelium
MMP-9 correlates 
well with 
histological scores 
of lung injury
Eichler  
et al. 2003
Pigs Cardiopulmonary bypass 
(hypothermic)
BAL MMP-2 and -9, 
AaDO2, PCWP, lung 
tissue water content
MMP-2 and MMP-9 
increased after CPB, 
MMPs correlated with 
AaDO2
Hirsh  
et al. 2004
Mice Neutropenic sepsis 
(cyclophosphamide+CLP)
Tissue homogenate 
MMP-2 and -9
Elevated MMP-2 and 9 
after CLP
Cyclophosphamide 
induced MMP-9 
activity
Cederqvist 
et al. 2006
Rats Hyperoxia BAL and tissue MMP-
2,-8,-9, trypsin
MMP-8 and MMP-9 
increased after 48 
hours
Castellheim 
et al. 2008
Pigs Live E.Coli bronchial  
instillation
Plasma MMP-9 Plasma MMP-9 
elevated, earlier than 
in i.v. infusion of 
Escherichia coli
IgA= immunoglobulin A; LPS= lipopolysaccharide; MMP= matrix metalloproteinase; BAL= broncho-alveolar lavage; 
TIMP= tissue inhibitor of metalloproteinases; AaDO2= alveolar-arterial oxygen difference; PCWP= pulmonary 
capillary wedge pressure; CBP= cardiopulmonary bypass; CLP= caecal ligation and puncture
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2. REVIEW OF THE LITERATURE
2.3.4. MMP-9 AND ACUTE LUNG INJURY
In ALI the recruited neutrophils and alveolar macrophages are important sources 
of MMP-9 (Fligiel et al. 2006), and the BAL MMP-9 levels correlate highly with 
neutrophil count (Ricou et al. 1996, Torii et al. 1997). In BAL of healthy controls, 
"'"'^!/:
is rich in neutrophils and lymphocytes (Torii et al. 1997). MMP-9 is also produced 
Q		;'/'QQ
and pulmonary endothelial cells (Gibbs et al. 1999, O´Kane et al. 2009). In a recent 
placebo-controlled study, intravenous salbutamol unexpectedly upregulated MMP-
9 production in vivo, and the effect was localized to distal lung epithelial cells 
(O´Kane et al. 2009). 
MMP-9 probably has a role in neutrophil recruitment because of its ability 
to process IL-8, the most potent neutrophil chemokine, into a more active form 
<=&;/'$$@>>'
mice with immune complex-mediated alveolitis, no differences emerged between 
$$@>>'%"'/''/"/<'=
MMP-9 may also play a role in permeability changes in the acute phase of lung 
injury, and its levels correlate highly with type IV collagen degradation product 
7S (Torii et al. 1997). Contradictory evidence comes from a clinical study in which 
changes in MMP-9 levels correlated inversely with extravascular lung water content 
/"<¢=	'>/"$$@>>'"'
decreased lung injury and better lung compliance after injury compared with their 
WT counterparts (Roscoe et al. 2001, Chetty et al. 2008). On the other hand, MMP-
9 may also be important in the healing process and in tissue remodelling; MMP-9 
was shown to be involved in the migration of alveolar epithelial cells (Buckley et 
al. 2001) and to be required for alveolar epithelial wound healing in vitro (O´Kane 
et al. 2009). In an experimental study on rats overexpressing MMP-9, bleomycin-
/'/Q;QQQ:$$@>';
';	`?^@>":'QQQ<Q
2007). Again, evidence from humans points in the opposite direction, as MMP-9 
;"Q"!/''			"
of collagen synthesis (Pugin et al. 1999b).
MMP-9 levels are elevated in ARDS patients compared with healthy controls 
(Torii et al. 1997) or hydrostatic pulmonary oedema patients (Pugin et al. 1999b). 
The levels are elevated early in the course of ARDS (O´Kane et al. 2009) and 
remain high several weeks in plasma and BAL of those ARDS patients who have a 
prolonged course of the disease (Ricou et al. 1996).  
?   <= / $$@> ;  ^ !/ : J 	

patients and found both latent and active forms of the enzyme in 5- to 80-fold 
higher concentrations compared with healthy controls, but the MMP-9 levels were 
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than in patients with hospital-acquired pneumonia in a small study by Lanchou et al. 
(2003). In that study, patients with rapidly resolving ARDS had a higher MMP-9/
TIMP-1 ratio on day 4 compared with patients with a longer course of the disease, 
although the MMP-9 levels were similar. In a study on paediatric ARDS patients, 
high levels of active MMP-9 in tracheal aspirate samples predicted longer need for 
mechanical ventilation (Kong et al. 2009) and the levels of active MMP-9 rose from 
day 2 to 6 of disease (Kong et al. 2011). The systemic MMP-9 levels in ALI are less 
well known. Ricou et al. (1996) found no difference in plasma MMP-9 concentration 
between healthy controls and ARDS patients, whereas some of the ARDS patients 
in another study had increased systemic pro-MMP-9 levels, although the overall 
>!""';"<@/b).
2.3.5. TIMP-1
TIMP-1 is expressed in numerous cell types and after hyperoxia-induced lung injury 
"{/'QQ'''
vascular endothelium (Veness-Meehan et al. 1991). TIMP-1 is present in the BAL 
!/<?'/="<'/=:
controls, and markedly elevated levels have been detected in BAL (Fliegiel 2006, 
Ricou 1996, Torii 1997) and plasma (Ricou et al. 1996) of ALI/ARDS patients. In 
a paediatric study, tracheal aspirate TIMP-1 levels were lower in ARDS patients 
than in patients intubated for non-pulmonary reasons (Kong et al. 2011). TIMP-1 is 
reported to be higher in plasma than in BAL (Ricou 1996), which is expected due to 
the dilution effect of BAL on secretions. TIMP-1 in neither plasma nor BAL seems 
to be correlated with the severity of lung injury or oxygenation disturbance (Ricou 
et al. 1996). However, high plasma levels of TIMP-1 were associated with worse 
outcome in one study (Ricou et al. 1996). In contrast, in another study BAL TIMP-1 
was not associated with outcome (Fliegiel et al. 2006). The balance of MMP-9 and 
%	$@>"Q!''/^
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'";'/:
(Ricou et al. 1996, Lanchou et al. 2003), and the low ratio was mainly due to higher 
TIMP levels (Ricou et al. 1996). Moreover, in a study of paediatric ARDS patients 
the BAL MMP-9/TIMP-1 ratio was higher in patients with a shorter (<10 days) 
course of the disease than those with a longer-lasting disease (Kong et al. 2009). 
One might speculate that MMP-9 levels are elevated locally and more than the 
actual level, the balance between the enzyme and its inhibitor might be important 
in determining the course of the disease towards either normal or exaggerated 
Q
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On the other hand, TIMP-1 has been suggested to participate in IL-6-mediated 
lung protection in a hyperoxic lung injury model in mice (Ward et al. 2000). In 
a study on mice genetically lacking TIMP-1, bleomycin caused more severe lung 
"/"/''/"/%	$@>>';/
(Kim et al. 2005). 
2.3.6. CORRELATIONS WITH OTHER INFLAMMATORY PARAMETERS
@>!""';"Q"!/'	>J
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receptor antagonist (Pugin et al. 1999b=	^!/:$$@>J
and MMP-9 have a strong intercorrelation (Fliegiel et al. 2006). The concentrations 
of MMP-8 (Fliegiel et al. 2006) and MMP-9 (Fliegiel et al. 2006, Ricou et al. 1996) 
'/'/^ !/%	$@>'
with BAL interleukin-6 (Ricou et al. 1996). 
2.3.7. MMP-8 AND -9 IN VENTILATOR-INDUCED LUNG INJURY 
In experimental studies, MMPs -8 and -9 have been described to participate in 
early phases of ventilator-induced lung injury (VILI). Whereas ventilation with high 
pressure rapidly induced MMP-8 in the WT animals, mice genetically lacking MMP-
J/"'""
"/:/%":/::'"Q
of the collagenolytic effect of MMP-8 and rather due to its immunomodulatory 
   '"    >!""
'	>*	>$$@>'"<Q'=$'
genetically lacking MMP-9, by contrast, exhibited more serious lung damage than 
their WT counterparts, suggesting that in VILI MMP-9 could be protective (Albaiceta 
et al. 2008). 
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2.4. MMPS IN ACUTE PANCREATITIS 
Acute pancreatitis is an example of a non-infectious condition where systemic 
!""   ;   ' "Q /Q'
are typical. Therefore, the presence of MMPs would not be surprising. Some 
experimental evidence of MMP-9 in association with AP exists, but to date no 
studies on MMP-8 or clinical studies on either MMP have been published. 
Experimental acute pancreatitis is characterized histologically by extensive 
acinar cell necrosis, haemorrhage, extensive neutrophil infiltration in the 
pancreatic tissue and activation of trypsinogen to active trypsin (Awla et al. 2012). 
These pathophysiological changes can be alleviated by an MMP inhibitor and 
 /' $$@>>'"'?/"$$@>" Q
an important mediator in activating trypsinogen in the acinar cells, which is a 
central pathophysiological feature in acute pancreatitis (Awla et al. 2012). On the 
other hand, trypsin is able to activate MMP-9 (Sorsa et al. 1997), thus creating a 
possible positive feedback loop. MMP-9 is elevated and extensively activated in 
!/"'/'<$/=
and it may be pathophysiologically relevant since by using a broad-spectrum MMP 
inhibitor, Batimastat, local and distant organ injury associated with experimental 
pancreatitis can be inhibited (Muhs et al. 2003). Neutrophils are involved in the 
pancreatitis-associated lung injury (Awla et al. 2012). Elevated MMP-9 in the lung 
/''/'/'$$@Q
(Keck et al. 2002). Furthermore, elevated MMP-9 has a good predictive value for 
predicting disease severity and pulmonary complications in acute pancreatitis 
models (Keck et al. 2006). 
2.5. MMPS AND CARDIAC ARREST
":"'!""Q>:'/"'"
 '">:/>' !"""	
immediate hypoxic-ischaemic damage to cells, tissue damage caused by ischaemia-
!""''/%':/Q:/>
induced oxidative and nitrosative stress, leading to the accumulation of reactive 
   '  '; :  !"" '' 	
ischaemia-reperfusion-associated tissue damage, neutrophil granulocytes and their 
products play a major role, especially in the development of microvascular damage 
and altered permeability (Granger et al. 1988).
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2.5.1. POST-CARDIAC ARREST SYNDROME
Cardiac arrest causes ischaemia and, after a successful resuscitation, reperfusion to 
all organs of the body. A term describing the entity of pathophysiological changes 
after successful resuscitation from cardiac arrest has been coined, namely the post-
resuscitation disease (Negovsky et al. 1995) or, more recently, post-cardiac arrest 
syndrome (Nolan et al. 2008). Accumulating evidence suggests that upregulated 
"'!"""";'"
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resembling septic states (Adrie et al. 2000), and slightly later adhesion molecules 
(Gando et al. 2000, Geppert et al. 2000) are seen after the return of spontaneous 
circulation (Callaway et al. 2008). As a sign of neutrophil activation, neutrophil 
elastase is rapidly upregulated, and elevation of soluble thrombomodulin marks 
endothelial damage (Gando et al. 2000). SIRS as a clinical syndrome is a frequent 
''<`=
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cardiac dysfunction, coagulation abnormalities and adrenal dysfunction have 
been described (reviewed by Adrie 2004). The degree of cardiac dysfunction was 
'%{?>;'"<{"*=
2.5.2. MMPS AND NEURONAL DAMAGE
MMPs, particularly MMP-7 and MMP-9, are pathophysiologically relevant in several 
/''!""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(Conant et al. 1999) and multiple sclerosis (Cossins et al. 1997). The BBB consists 
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1990), which are all substrates for MMP-9.
In the brain, endothelial cells, neurons, microglia, astrocytes and oligodendrocytes 
secrete MMP-9 (Conant et al. 1999, Rivera et al. 2002, Rosenberg et al. 2001), and 
''Q"/Q%{?><=$$@"'/
tissue injury in the brain in several ways, e.g. degradation of the ECM, disruption of 
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"!/:!""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into the brain causes upregulation of MMP-9 and a simultaneous increase in the 
permeability of the BBB, which can be inhibited by an MMP inhibitor (Rosenberg et 
#=%/$$@>"''"""Q'
induced by cytokines (Rosenberg et al. 1995). Activated MMP-9 promotes neuronal 
apoptosis in vitro (Gu et al. 2002). However, MMPs may also exert neuroprotective 
functions, and they probably play a role in ECM remodelling, revascularization and 
neuronal growth after injury (Morancho et al. 2010).
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2.5.3. MMP-9 IN ISCHAEMIC STROKE
In experimental stroke, microvascular occlusion and accumulation of neutrophils 
are early features. By 6-12 hours from the insult, neutrophils have invaded the 
brain parenchyma (Garcia et al. 1994, Akopov et al. 1996), and the abundance of 
neutrophils is associated with outcome (Akopov et al. 1996). Substantial damage 
to the microvascular basement membranes with a loss of basement membrane 
'"'/"Q'	''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after cerebral ischaemia and reperfusion (Hamann et al. 1995). MMP-9 participates 
in the breakdown of the basement membranes during experimental focal ischaemia 
(Rosenberg et al. 1996). Upregulation of MMP-9 can be seen after experimental 
focal ischaemia in the neurons, accumulated neutrophils (Rosenberg et al. 2001) 
and cerebral vessels (Wagner et al. 2003). In patients with acute stroke, serum 
MMP-9 levels rise early, within 3 hours (Montaner et al. 2003), peak at 24 hours 
(Montaner et al. 2001a) and stay elevated for at least 12 days (Horstmann et al. 
2003). MMP-9 levels correlate with infarct volume and are associated independently 
with clinical severity of stroke (Montaner et al. 2001a). Elevated plasma MMP-9 
independently predicts spontaneous (Montaner et al. 2001b, Castellanos et al. 2003) 
and t-PA treatment-associated (Montaner et al. 2003) haemorrhagic transformation 
:'Q:';;''<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2003, Montaner et al. 2003). MMP-9 levels are associated with the severity of the 
haemorrhage (Montaner et al. 2003). Furthermore, patients with a large medial 
'Q:'$$@>'/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MMP-3 may be important in protecting neurons from delayed death via apoptosis 
(reviewed by Cunningham 2005). Monocytes from stroke patients express increased 
levels of MMP-7 mRNA, MMP-9 mRNA and TIMP-1 mRNA (Kouenhowen et al. 
2001). In experimental stroke, TIMP-1 levels in the brain tissue increase by 48 
hours after ischaemia (Rosenberg et al. 1998). Serum TIMP-1 in patients seems to 
be unaffected by ischemic stroke (Horstmann et al. 2003).
2.5.4. MMPS AND TIMP-1 IN GLOBAL CEREBRAL ISCHAEMIA 
Ischaemic stroke represents focal cerebral ischaemia with damage to the BBB and 
:/"!""'''/'"
and reperfusion with delayed damage to selective neuronal populations such as 
hippocampal neurons or caudate nucleus neurons (reviewed in Cunningham 2005). 
 ' /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global ischaemia in rodents, active MMP-9 is upregulated in microglia, astrocytes 
(Rivera et al. 2002) and neurons at such brain regions as hippocampus (Rivera et 
al. 2002, Lee et al. 2004) and nucleus caudatus, preceding neuronal death (Magnoni 
*=%"'"/'/'
MMP-9 knock-out mice or by using a broad-spectrum MMP inhibitor BB-94 (Lee 
et al. 2004).
TIMP-1 was increased after global cerebral ischaemia (Romanic et al. 1998, Rivera 
et al. 2002). TIMP-1 protected hippocampal neurons from glutamate exitotoxicity in 
culture, at least partially independent of its MMP inhibitory actions (Tan et al. 2003).
2.5.5. POSSIBLE THERAPEUTIC MECHANISMS OF MILD HYPOTHERMIA 
TREATMENT (MTH)
In 2002, two clinical trials showed that mild therapeutic hypothermia improved 
neurological outcome and survival of comatose out-of-hospital cardiac arrest 
patients (Bernard et al. 2002, Hypothermia After Cardiac Arrest Study Group 2002). 
Therapeutic hypothermia is currently a standard treatment for comatose out-of-
'''/;;'/Q
as the presenting arrhythmia (Nolan et al. 2003). However, it is not fully clear how 
hypothermia treatment protects cells from injury after cardiac arrest. Mechanisms 
/'/ !""'"Q' /
decreased oxygen demand, altered neurotransmitter release, moderate anticoagulant 
effect, and inhibition of vasoconstrictive substances have been proposed (reviewed 
in Campos 2012). From animal studies on focal ischaemia, hypothermia is known 
to reduce infarct size and preserve the BBB, with a concomitant reduction in MMP-
9 levels and activity in the area of BBB breakdown (Wagner et al. 2003). In a 
mouse model of focal ischaemia, hypothermia reduced MMP-9 and plasminogen 
activators in the brain, thus inhibiting the breakdown of type IV collagen in the BBB 
(Burk et al. 2008). Hypothermia also reduced the ischaemia-induced expression 
of the apoptosis receptor Fas and decreased the soluble form of the Fas ligand, 
thus reducing apoptosis. Similar effects were seen by using an MMP inhibitor, and 
combining the inhibitor and hypothermia produced additive effects (Liu et al. 2008). 
In a clinical study comparing systemic MMP-9 levels between different treatment 
groups in stroke patients, MMP-9 levels were lowest in patients treated with MTH 
(Horstmann et al. 2003). MMP-9 levels correlated positively with body temperature 
in another study on stroke patients who did not receive hypothermia treatment 
(Montaner et al. 2001). Considering the results of these studies on focal cerebral 
ischaemia, the protective mechanisms of hypothermia might include suppression 
of MMP-9 also in the context of global cerebral ischaemia. Evidence from studies 
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on hypothermia in other disease entities, such as traumatic brain injury support the 
hypothesis that hypothermia may be associated with suppressed MMP-9 levels. In 
experimental traumatic brain injury, post-traumatically elevated MMP-9 in brain 
tissue was suppressed in the animals treated with mild hypothermia (Truettner et 
al. 2005). 
2.5.6. MTH AND SYSTEMIC INFLAMMATION
<J=::'"'';
between normothermia- and hypothermia-treated rats, but expression of ICAM-1 
adhesion molecules was slightly delayed in the hypothermia group. In a clinical 
observational study of 71 out-of-hospital cardiac arrest patients, MTH did not 
::'%{?>Q/  ;: 	> '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group. However, in that study the MTH group had markedly increased prevalence 
:Q'''";::'!""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the authors did not report time intervals from basic CPR or ROSC. Furthermore, 
::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normothermia groups, in contrast to other studies (Fries et al. 2009). In a model 
of experimental intestinal ischaemia, hypothermia treatment prevented neutrophil 
accumulation into the lungs, thus providing indirect evidence that hypothermia 
treatment might protect organs from ischaemia-reperfusion-induced systemic 
!""<=
2.6. PERFORMANCE AND INTERPRETATION OF STATISTICAL 
ANALYSES OF A BIOMARKER
A biomarker is a 


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

what is normal, therefore providing a frame of reference for predicting or detecting 
what is abnormal” (Dalton et al. 2006).
For a biomarker to prove useful in clinical practice, it should be shown to differ 
' Q    ;/  ;/
diagnostic properties, perform better or non-inferiorly relative to existing tests and 
increase the information available for clinical decision-making. It should also be 
demonstrated to modify outcome when used in decision-making. Furthermore, the 
pathophysiological basis should be understood (Ray et al. 2010).
To evaluate the diagnostic or predictive properties of a biomarker, statistical 
" /'  ; '' ;  ; 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and likelihood ratios, are calculated. These terms are also useful for comparing 
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performance of a test with others and for determining whether the test gives 
additional information for clinical decision-making.
When examining the performance of a biomarker in diagnostics or outcome 
';'';;';;/
of the marker can be calculated by using a matrix:
Table 7. Matrix for calculating statistical metrics 
Test Disease present Disease absent
Positive A B
Negative C D
Modiﬁed from Marshall et al. 2009 and Ray et al. 2010
Sensitivity= Ability of the test to identify patients who truly have the disease= A/A+C
Speciﬁcity= Ability to rule out the patients who truly do not have the disease=D/B+D
Positive predictive value= Likelihood that the disease is present in the case of a positive test 
result=A/A+B
Negative predictive value= Likelihood that the disease is absent in the case of a negative test 
result= D/C+D
Positive likelihood ratio (LR+) =Ratio of “true positive” measurements (=sensitivity) to “false 
positive” measurements (=1-speciﬁcity) = sensitivity/1-speciﬁcity
Negative likelihood ratio (LR-) = Ratio of “false negative” measurements (1-sensitivity) to “true 
negative” measurements (speciﬁcity) = 1-sensitivity/speciﬁcity
Accuracy= Proportion of true results (true positives and true negatives) of all measurements= 
A+D/A+B+C+D
;'''";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positive and negative predictive values are affected by the prevalence of the disease. 
Likelihood ratios can be calculated for different levels of the test. A graphical plot 
reconstructed from the likelihood ratios of individual measurements produces 
the ROC curve. By calculating the area under the (ROC) curve (AUC), the 
discriminative power of the test can be evaluated (Ray et al. 2010, Marshall et al. 
2009). A rule of thumb for evaluating the performance of a biomarker in diagnostics 
or outcome prediction suggests the following limits: LR+>10 and AUC>0.90 for 
excellent performance, LR+ 5-10 and AUC 0.75-0.90 for good performance, LR+ 
1-5 and AUC 0.50-0.75 for poor performance and LR+=1 and AUC 0.5 for no 
diagnostic or predictive value (Ray et al. 2010).
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3. AIMS OF THE STUDY
The role of neutrophil-derived matrix metalloproteinases and their inhibitors in 
::'"'!""";:'
and organ dysfunction, but also in ischaemia/reperfusion injury was investigated. 
Detailed aims of the study are described below.
1. To examine the systemic levels of MMP-7 (III), MMP-8 (I, II, III ) and MMP-9 (II, 
III) and their inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1) (II, III), in 
septic and non-septic groups of critically ill patients compared with healthy controls. 
2. To evaluate the local levels of MMP-8 in an infected organ compartment and 
compare its local levels with its serum and urine concentrations in a patient group 
with secondary peritonitis (I).
3. To examine the association of systemic MMP-8 (II, IV), MMP-9 (II) and TIMP-1 
(II, IV) levels with mortality in patients with severe sepsis or septic shock. 
4. To evaluate MMP-8 and TIMP-1 in outcome prediction in a large group of patients 
presenting with acute respiratory failure and in a subgroup of patients with ALI/
ARDS (IV).
5. To investigate the association of mild therapeutic hypothermia treatment with 
serum MMP-7, MMP-8, MMP-9 and TIMP-1 levels (III).
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4. PATIENTS AND METHODS
4.1. PATIENTS
This study comprised four separate patient populations and a group of healthy 
volunteers. The patient group in Study I was collected solely for the purposes of 
this study and Studies II, III and IV were substudies of large multi-centre studies. 
Patient groups for individual studies are described in detail in Table 8 below.
Table 8. Study patients.
Study Study I Study II Study III Study IV
Setting 2 ICUs in a University 
Hospital
24 Finnish ICUs From one centre (Helsinki) 
in a multi-centre study
25 Finnish ICUs
Study 
conduction 
time
9 months
January 1- September 
30, 2004
4 months
November 1- 
February 28, 
2005
3 years, 4 months
March 1997- June 2000
8 weeks
April 16- June 
10, 2007
Design and 
name of the 
study
Prospective 
observational
Prospective 
observational.
FINNSEPSIS
Retrospective laboratory 
analysis from a prospective 
randomized controlled 
study.
HACA
Prospective 
observational.
FINNALI
Primary 
inclusion 
criteria
Surgically conﬁrmed 
secondary peritonitis
Severe sepsis 
or septic shock 
(ACCP/SCCM 
criteria)
Witnessed cardiac arrest of 
presumably cardiac origin 
(absence of pulse and 
spontaneous respiration)
Mechanical 
ventilation for 
more than 6 
hours
Other inclusion 
criteria
Age >18 years Age >18 years -Age 18-75 years
-VT/VF as initial rhythm
-ROSC < 60 minutes
-Time from collapse 5-15 
minutes until resuscitation 
attempts by emergency 
medical personnel
Age >16 years
Exclusion 
criteria
-Metastasing 
malignancy
-Haematological 
malignancy
-HIV, 
immunocompromising 
disease, 
immunosuppressive 
medication
-Tetracycline or 
bisphosphonate use
-CA due to intoxication or 
trauma
-Collapse in the presence 
of medical personnel
-Response to verbal 
command
-Hypothermia (<30°C on 
admission)
-Terminal illness, 
coagulopathy or pregnancy
-Sustained hypotension or 
hypoxemia
-Immuno-
compromised 
patients
-Systemic 
corticosteroid 
use
-Cytostatic 
medication
Inclusion time 
to study
<72 hours from 
surgery
When inclusion 
criteria ﬁrst 
met
On arrival at the 
emergency department
After 6 hours 
of mechanical 
ventilation
Number of 
patients/ 
Consent 
to blood 
samples/ Total 
number of 
patients in the 
original study
15 248/ 254/ 470 51/70
Hypothermia 30/36
Normothermia 21/34
563/ 656/ 958
ICU= intensive care unit; VT= ventricular tachycardia; VF= ventricular ﬁbrillation; ROSC= 
restoration of spontaneous circulation; CA= cardiac arrest
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In Studies I and III, the inclusion of individual patients was assessed by the study 
investigators. In Studies II and IV, this was done by the treating clinicians on 
the basis of written criteria. Patients in Studies I, II, and IV received standard 
treatment in the ICUs. Patients in Study III were randomized to receive either 
mild therapeutic hypothermia with active cooling to 33 +-1°C for 24 hours or 
normothermia. Normothermia treatment included passive warming after possible 
spontaneous hypothermia on arrival to a body temperature of less than 38°C, where 
the temperature was then maintained. Hypothermia was induced with an external 
cooling device, and after 24 hours of hypothermia patients were rewarmed over 
an 8-hour period.
4.2. CONTROLS
Ten healthy controls with no medications served as a control group for blood (I, 
II, III) and urine (n=9) (I) samples. All controls gave informed consent before 
sample collection. 
4.3. DATA COLLECTION 
Data were collected manually in Studies I and III as well as partly in Studies II 
and IV. In Studies II and IV, intensive care diagnoses, clinical variables, severity 
scorings and organ failure scorings, and ICU mortality were obtained from the 
Finnish Intensive Care Consortium (Intensium Ltd., Kuopio, Finland). Hospital 
mortality in Studies I, II and III were assessed by investigators. Data considering 
30-day and 90-day mortality were obtained from Statistics Finland (IV). 
Demographic data, chronic illnesses and medications were recorded in all studies. 
Source of infection, microbiological data and antibiotic treatment were recorded (I, 
II). The aetiology of cardiac arrest was assessed by a specialist in cardiology. The 
presence of ALI/ARDS was determined by ICU clinicians and radiologists in the 
admitting hospital. Risk factors for ALI/ARDS were recorded (IV).
APACHE II (Knaus et al. 1985) (I, II) and SAPS II (LeGall et al. 1993)( II, 
IV) were used as measures of disease severity, and daily calculations of SOFA 
scores ( Vincent et al. 1998) (I, II, IV) were used for organ failure assessment. In 
Study I Mannheim peritonitis index (Wacha et al. 1987) was calculated. Use of 
hydrocortisone in the treatment of septic shock was recorded in Studies I, II and 
IV. Laboratory parameters recorded included C-reactive protein (CRP), white blood 
'<^='/''//			/>''
enolase, S-100B-protein, troponin T (TnT) and creatinine kinase (CK) and its MB 
fraction (CK-MB). 
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4.4. DEFINITIONS 
;''Q/@
$'<^
='""'!""/''":'
and acute organ dysfunction, and in the case of septic shock, also persistent 
hypotension (II). Severe organ dysfunction or organ failure was pronounced when 
the SOFA score was 3 or more in an individual organ system (II).
'QQ':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respiration (III). 
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mechanical ventilation either with non-invasive or invasive interface (IV). ALI and 
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4.5. SAMPLES FOR MMP AND TIMP-1 ANALYSES
4.5.1 BLOOD SAMPLES
In Studies I, II and IV, informed consent was required for collection of blood samples. 
In Study III, the ethics committee had waived the need for informed consent and 
a deferred consent was used for all patients. 
Time-points for sample collection were the day of inclusion (I, II), 24 and 48 
hours after ROSC (III) and at inclusion to the study and 48 hours thereafter (IV). 
The blood samples in Study I were taken at the same time as urine and peritoneal 
!/"
Blood samples were drawn from an arterial line or venous indwelling catheters 
into a vacuum glass tube. Blood samples from healthy controls were taken from a 
peripheral vein. The samples were allowed to clot at room temperature and then 
centrifuged. The supernatants were separated and divided into aliquots and stored 
at -18°C (III) to -20°C until analysis. The samples in Study III were stored initially 
at -18°C and then at -70°C until taken to the analysing laboratory. 
4.5.2. URINE AND PERITONEAL FLUID SAMPLES 
+<"=:"/'@!/"
taken from peritoneal drainage tubes placed on clinical indication in laparotomy. 
%/!/"'''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until analysis. 
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4.6. LABORATORY ANALYSES
4.6.1. MEASUREMENT OF PERITONEAL FLUID COLLAGENASE ACTIVITY (I)
%"''; !/ 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for 12 hours at 22°C. This was done with and without 1 mmol/L aminophenyl 
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75%) cleavage products were separated by 8% sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis (Hanemaaijer et al. 1997).
4.6.2. WESTERN IMMUNOBLOTTING (I)
'''Q<	`: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(Hanemaaijer et al. 1997) and against MMP-1 and MMP-13 (Lauhio et al. 1994c, 
Lindy et al. 1997) were used.  Samples were mixed with Laemmli buffer without 
reducing agents and heated for 5 minutes at 100°C, followed by protein separation 
by using 10% SDS polyacrylamide gels. Target enzyme detection was performed by 
using an enhanced chemiluminescence (ECL) Western blotting system according to 
the manufacturer´s instructions (Amersham Pharmacia Biotech, Buckinghamshire, 
+= % ""/Q  / Q  ^>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Densitometer using the Molecular Analysis program (Bio-Rad Laboratories Inc., 
&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mesenchymal-type MMP-8 as well as for MMP-1 and MMP-13 (Hanemaaijer 1997).
4.6.3. TIME-RESOLVED IMMUNOFLUOROMETRIC ASSAY (IFMA) FOR MMP-8 
ANALYSES (I, III, IV)
%$$@>J'' /"<	 			 	=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8708 and 8706 (Medix Biochemica, Kauniainen, Finland) were used as a catching 
antibody and a tracer antibody, respectively.  The tracer antibody was labelled using 
europium chelate (Hemmilä et al. 1984). The assay buffer contained 20 mmol/L 
Tris-HCl, pH 7.5, 0.5 mol/L sodium chloride, 5 mmol/L CaCl2#¦"
¨2, 
0.5% bovine serum albumin, 0.05% sodium azide and 20 mg/L diethylenetriamine 
penta-acetic acid. The assays were performed on microtitration plates in two steps. 
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mouse serum were pipetted into the wells. After incubation, the wells were washed 
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III, the levels of MMP-8 were expressed as ng/ml. 
4.6.4. MEASUREMENT OF MMPS AND TIMP-1 BY ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA)
The serum concentrations of MMP-7 (III), MMP-8 (II), MMP-9 (II, III) and TIMP-1 
(II, III, IV) were measured by enzyme-linked immunosorbent assay (ELISA), as 
previously described by Rautelin et al. (2009). Based on manufacturer information, 
this method measures active, pro-, complexed and fragmented forms of MMPs 
and TIMP-1. Commercial kits were used for the determinations of concentrations 
(Biotrak ELISA System; Amersham Biosciences, Buckinghamshire, UK). For TIMP-
1 in Study III DuoSet ELISA Development Systems (R&D Systems, Minneapolis, 
MN, USA) were used. The analyses were performed following instructions from 
"/:'/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"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variability for the Biotrak ELISA System Kit are 2.1% and 2.4% for MMP-7, 2.5% 
and 4.1% for MMP-8, 8.2% and 9.9% for MMP-9 and 9.3% and 12.4% for TIMP-1, 
respectively. The corresponding detection limits are 0.16 ng/ml, 0.032 ng/ml, 0.6 
ng/ml and 1.25 ng/ml.
4.7. OUTCOME MEASURES
In Study II, the primary outcome measure was ICU mortality. In Study III, the 
original design included neurological recovery as a primary outcome, measured by 
the Pittsburgh Outcome Scale (CPC) and 6-month survival as a secondary outcome, 
but these outcome measures were not used for the purposes of this study. In Study 
IV, the primary outcome measure was 90-day mortality. 
4.8. STATISTICAL METHODS
The statistical analyses were performed by using SPSS 10.1. for Windows (SPSS 
Inc., Chicago, IL, USA) (I, III). For Study IV SPSS statistics version 20.0 (SPSS, 
Chicago, IL, USA) was used. Analyses for Study II were performed by using Graph 
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Pad Prism version 4 (Graph Pad Inc., San Diego, CA, USA). 
Data were presented as median and interquartile range, absolute value and 
percentage, or mean and standard deviation (SD) / standard error of mean (SEM) 
as appropriate. pª#''':'
tests and logistic regression analyses, where pª''
pª''/			
For comparisons of categorical data between groups, Fisher’s exact test was used.
Due to the assumed non-normal distribution of the laboratory parameters, the 
Mann-Whitney U-test was used for comparisons of continuous variables between 
independent groups, and the Kruskall-Wallis test was used for comparisons of 
continuous variables between several independent groups. In Study II, comparisons 
between groups were also performed with unpaired t-test. For comparisons of 
laboratory variables within a group (I) Wilcoxon´s signed-rank test was used. 
In Study III, the comparison of laboratory variables between groups at two 
different time-points was performed by calculating changes over time in these 
variables and then calculating the differences between means (DIM) of these changes 
#'';<`/*=
Stepwise multivariate logistic regression analysis was performed to study the 
independent effect of a variable on outcome (IV).
Receiver-operator characteristic (ROC) curve analysis was performed to assess 
the ability of a variable to predict outcome (IV). The optimal cut-off values were 
Q;/:;QQ'';
This was done by using the Youden method, identifying the point with the greatest 
distance on the ROC curve from the line of equality (Youden 1950). After identifying 
'/>::;/;<«=#'';
(95% CI) for the cut-off values in predicting outcome were calculated (IV).
%/'/;<+=''/#'';
(IV). An AUC of 0.5 represents performance on the test equalling random chance, 
whereas a perfect test would yield AUC 1. 
Spearman’s Rho test was used to evaluate correlations between non-parametric 
variables (IIII, IV). 
Kaplan-Meier survival curves were constructed according to quartiles of 
admission MMP-8 and TIMP-1 values (IV) to demonstrate the difference in 90-
day mortality. 
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5. RESULTS
5.1. CHARACTERISTICS OF PATIENTS
The studies comprise a total of 877 patients. Characteristics of patients, clinical 
severity scores and outcome are summarized in Table 9.
Table 9. Patient and treatment characteristics, clinical severity scorings and outcome.
Study I II III IV
Study diagnosis Secondary 
peritonitis
Severe sepsis or septic 
shock
Cardiac arrest Acute 
respiratory 
failure
Number of patients 15 248 51 563
Age, years 63 (54-74) 60 (49-72) 59 (52-67) 64 (52-75)
Gender male 10 (66.7) 170 (70) 41 (80) 375 (67)
Need for vasoactive 
therapy
13 (86.7) 186 (75) na 289 (56)*
Corticosteroid during 
study
5 (33) 71 (29) 2 (3.9) na
WBC count (x109/L) on 
study admission
8.1 (6.2-10.6) na 11 (9-14.4) 10.5 (8-14.6)
CRP (mg/L) on study 
admission
263 (139-327) na 5 (5-6) 51 (9-160)
Serum creatinine 
(μmol/L)
83 (67-113) na na 75 (57-117.5)
Patients with 
immunosuppressive 
medication 
0 28 (11) corticosteroids
12 (5) cytostatic drugs
0 0
SOFA on admission 8 (5-9) 8 (6-9) na 8 (5-10)
Highest SOFA 8 (5-9) 10 (8-13) na 9 (6-12)
APACHE II 13 (8-17.5) 24 (18-29) na 23 (16-29)
SAPS II na na na 42 (29-55)
ICU mortality na 33 (13) na 52 (9)
Hospital mortality 2 (13.3) 62 (25) 10 (20) 116 (21)
90-day mortality na na na 152 (27)
Values are presented as number (%) or median (interquartile range). * Vasoactive therapy on 
admission. WBC= white blood cells; CRP= C-reactive protein; SOFA= Sequential Organ Failure 
Assessment; APACHE II= Acute Physiology and Chronic Health Evaluation score II; SAPS II= 
Simpliﬁed Acute Physiology Score II; ICU= intensive care unit; na= not assessed.
In Studies II and III, the patients were comparable with the patients from the 
original studies without laboratory samples. Patients receiving immunosuppressive 
"'<_='/:"/	
description of disease characteristics, laboratory variables and therapy for Study 
III is provided in Table 10. 
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Table 10. Disease and treatment characteristics and laboratory variables in Study III.
Initial rhythm VF, n (%) 50 (98)
Basic life support, n (%) 21 (42)
Myocardial infarct, n (%) 31 (61)
Primary arrhythmia, n (%) 12 (24)
Thrombolysis, n (%) 20 (39)
Hypothermia treatment, n (%) 30 (59)
Time to ROSC, minutes, median (IQR) 17 (13-22)
Temperature on arrival to hospital, °C, median (IQR) 35.3 (34.7–35.9)
NSE at 24 hours, μg/L, median (IQR) 10.2 (7.7–13.5)
S100 at 24 hours, μg/L, median (IQR) 0.13 (0.1–0.17)
Troponin t at 24 hours, μg/L, median (IQR) 0.54 (0.09–1.71)
Data are presented as absolute values (%) or medians (interquartile range).  VF= Ventricular 
ﬁbrillation; ROSC= restoration of spontaneous circulation; NSE= Neuron-speciﬁc enolase. 
The risk factors for acute respiratory failure (IV) for the study population and the 
ALI/ARDS subgroup are presented in Table 11.
Table 11. Type of admission and risk factors for acute respiratory failure in Study IV patients.
Condition within 48 hours of ICU 
admission
Non-ALI/ARDS patients 
(n= 520), n (%)
ALI/ARDS subgroup  
(n= 43), n (%)
Sepsis 61 (12) 12 (28)
Pneumonia 49 (10) 11 (26)
Infection 14 (3) 9 (21)
Cardiac insufficiency 111 (22) 11 (26)
Intoxication 33 (6) 5 (12)
Impaired consciousness 151 (29) 9 (21)
Neuromuscular disease 10 (2) 1 (2)
Suspected or conﬁrmed aspiration 83 (15) 12 (28)
Pancreatitis 14 (3) 3 (7)
Trauma 34 (7) 1 (2)
Massive transfusion 33 (6) 3 (7)
Elective admission 95 (18) 0 (0)
Operative admission 214 (41) 7 (16)
Data are presented as absolute values and percentages. ICU= intensive care unit; ALI= acute lung 
injury; ARDS= acute respiratory distress syndrome.
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5.2. LEVELS OF MMP-8 IN SERUM AND BODY FLUIDS (I-III)
%/";:$$@>J';'"
controls (I-III) (error in study III, where a difference in MMP-8 is reported as not 
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The MMP-8 levels in the sera of patients were 200-fold those in urine. The 
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%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type MMP-8 by immunoblotting (I).
The admission levels of serum MMP-8, MMP-9 and TIMP-1 in study patients 
and controls are shown in Figure 4.
Figure 4. Systemic MMP-8 (a), MMP-9 (b) and TIMP-1 (c) in the study patients and controls: a) MMP-8 
levels were elevated in all study groups. b) MMP-9 was evaluated in patients with sepsis or septic shock 
(II) and in patients resuscitated from cardiac arrest. MMP-9 levels in study III appear higher than those 
in study II. c) Levels of TIMP-1 vary according to the study group, with the highest levels in patients 
with severe sepsis or septic shock.    
4a)
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4b)
4c)
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5.3. SYSTEMIC LEVELS OF OTHER MMPS AND TIMP-1 IN 
DIFFERENT PATIENT POPULATIONS AND COMPARISON WITH 
CONTROLS (II-IV)
MMP-7 was slightly elevated in cardiac arrest patients relative to controls, but 
';:p<0.01 chosen for this study (III). MMP-9 
concentrations were higher in patients than in controls (II, III). TIMP-1 levels, by 
contrast, were lower in cardiac arrest patients than in controls. These differences 
'
5.4. CORRELATION OF MMPS AND TIMP-1 WITH CLINICAL AND 
LABORATORY VARIABLES (II)
MMP-8 correlated weakly with TIMP-1 (rs 0.344, p<0.001) and admission SOFA 
(rs 0.208, p= 0.001), but not with APACHE II score in severe sepsis or septic shock 
%	$@>'""'/<rs 
0.569, p<0.001), moderately with SOFA score (rs 0.449, p<0.001) and weakly with 
APACHE II score (rs 0.351, p< 0.001) in these patients (unpublished results).
5.5. ASSOCIATION WITH OUTCOME (II, IV)
The association of MMP-8 (II, IV), MMP-9 (II) and TIMP-1 (II, IV) with mortality 
was investigated in severe sepsis or septic shock patients and in a large, unselected 
patient population with acute respiratory failure. Of the latter, 13% of the patients 
had sepsis on admission. When comparing admission MMP-8 levels between ICU 
/;;>/;;'<p<0.01) higher median MMP-8 levels 
were found in non-survivors, median 66.1 ng/ml (IQR 23.9 - 157.6 ng/ml) vs 149.6 
ng/ml (IQR 41.8 - 477.1 ng/ml), respectively (II). Similarly, in acute respiratory 
failure patients, MMP-8 levels were higher in ICU non-survivors than survivors 
(p=0.013). The difference in MMP-8 levels in Study II was no longer present when 
comparing hospital survivors and non-survivors (unpublished results). In Study IV, 
MMP-8 levels were similar between 90-day survivors and non-survivors. The ROC 
curve for MMP-8 and 90-day mortality is presented in Figure 5. 
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Figure 5. ROC curve: Performance of MMP-8 in predicting 90-day mortality in acute respiratory 
failure patients.
The area under the curve (AUC) was 0.546 (95% CI 0.491-0.601).
Median MMP-9 levels in ICU survivors, 158.7 ng/ml (IQR 66.5 - 251.9 ng/ml), 
	+>/;;J
"<	¬>
"=::'
(p=0.047), with lower values in non-survivors. The difference was no longer present 
when assessing 28-day mortality. 
%	$@>;''"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6 shows the comparison of admission serum TIMP-1 concentration between a) ICU 
survivors and non-survivors in Study II and b) 90-day survivors and non-survivors 
in Study IV. 
66
5. RESULTS
 6b) 
Figure 6. Comparison of admission serum TIMP-1 concentration between a) ICU survivors and 
non-survivors in Study II and b) 90-day survivors and non-survivors in Study IV.
6b) 
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TIMP-1 was an independent predictor of 90-day mortality and had an AUC of 
0.633 (95% CI 0.580-0.686) in ROC analysis. This association was also present in 
elective patients included in the study, as shown in Figure 7. 
Figure 7. ROC curve: TIMP-1 in predicting 90-day mortality of acute respiratory failure patients 
with elective admissions.
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5.6. ASSOCIATION WITH HYPOTHERMIA TREATMENT (III) 
Patients who did (n=30) and patients who did not receive therapeutic hypothermia 
"<_=::$$@>;Q"'
taken 24 hours from ROSC. At this time, all patients in the hypothermia group 
had reached the target temperature. The comparison of serum MMP-7, MMP-8, 
MMP-9 and TIMP-1 values between the two patient groups is shown in Table 12.
Table 12. Comparison of serum MMP-7, MMP-8, MMP-9 and TIMP-1 values between 
hypothermia-, and non-hypothermia-treated patients at 24 hours from ROSC.
MMP-7, ng/ml (IQR) MMP-8, ng/ml (IQR) MMP-9, ng/ml (IQR) TIMP-1, ng/ml (IQR)
Non-hypothermia 
(n=21)
0.4 (0-1.9) 40.5 (27.1- 78.3) 372 (251.5-419.5) 77.4 (58.6-90.0)
Hypothermia 
(n=30)
0.5 (0.1-1.6) 24.2 (17.7-41.5) 147.5 (101.8-280) 81.6 (53.8-96.5)
p-value 0.69 0.02 0.001 0.48
Data are presented as median (interquartile range). P<0.01 was considered signiﬁcant. MMP= 
matrix metalloproteinase, TIMP= tissue inhibitor of metalloproteinases, IQR= interquartile range
In the second sample, taken at 48 hours, when none of the patients were hypothermic, 
no differences were present between the groups in any of the measured MMPs or 
TIMP-1. The change from 24 hours to 48 hours in MMP-9 concentrations between 
/'<p<0.001), whereas in MMP-7, MMP-8 and TIMP-1 
the change was similar between groups. The median MMP-9 levels at 24 and 48 
hours from ROSC for both groups are presented in Figure 8. 
Figure 8. Median MMP-9 levels at 24 and 48 hours from ROSC for patients treated with 
hypothermia (n=30) and the patients with no hypothermia treatment (n=21). MMP-9 levels were 
lower in patients treated with hypothermia at 24 hours. The difference in changes over time (from 
24 to 48 hours) was signiﬁcant between groups.
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5.7. MMP-8 AND HYDROCORTISONE TREATMENT (II)
Hydrocortisone was used to treat 33% (I), 29% (II) and 3.9% (III) of patients. In 
Study II, the association of hydrocortisone treatment with admission MMP-8 and 
-9 levels was examined. No difference was detected in the levels of either enzyme 
relative to the use of corticosteroids.
5.8. ASSOCIATION WITH OXYGENATION DISTURBANCE (IV)
MMP-8 levels had a weak negative correlation (rs =-0.162, p<0.001) with the degree 
:/Q'Q@2/FiO2 ratio. TIMP-1 (p<0.01), but not 
MMP-8 (p_#='	
/Q/
patients. The ability of TIMP-1 to predict 90-day mortality in patients with ALI/
ARDS was moderate to good, with an AUC of 0.686 (95% CI 0.524-0.847, p=0.03). 
At the cut-off level of 418 ng/ml, TIMP-1 had a positive likelihood ratio of 2.60 (95% 
CI 1.13-6.00) for 90-day mortality. TIMP-1 had a weak negative correlation (rs = 
-0.260, p<0.001) with the degree of oxygenation disturbance in the whole patient 
population. Figure 9 displays the TIMP-1 levels in the quartiles of PaO2/FiO2.
Figure 9. Admission serum TIMP-1 levels relative to oxygenation disturbance. The oxygenation 
disturbance is represented by the PaO2/FiO2 ratio from the 6 hours before inclusion in the study. 
The PaO2/FiO2 values for individual patients are divided into quartiles. The differences in TIMP-1 
levels over the quartiles were signiﬁcant.
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5.9. POST HOC ANALYSES OF MMP-8, MMP-9 AND TIMP-1 IN 
PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK (II) AND 
ACUTE RESPIRATORY FAILURE (IV) (UNPUBLISHED RESULTS)
MMP-8 performed moderately in predicting ICU mortality, but not 28-day mortality 
of septic patients. TIMP-1 performed well in predicting ICU mortality and moderately 
'J>"%/'/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intervals for admission MMP-8, MMP-9 and TIMP-1 in predicting ICU and 28-
day mortality of patients with severe sepsis or septic shock are shown in Table 13.
At the cut-off-level of TIMP-1 2713 ng/ml, the LR+ was 3.82 (95% CI 2.57-
5.66) for ICU mortality.  The optimal cut-off value for TIMP-1 in predicting 28-day 
mortality was 1727 ng/ml. At this cut-off level, LR+ was 1.75 (95% CI 1.38-2.21).
Table 13. AUCs with 95% conﬁdence intervals for MMP-8, MMP-9 and TIMP-1 in predicting ICU 
and 28-day mortality of patients with severe sepsis or septic shock. For comparison, the AUCs 
for APACHE II score and maximal lactate on day one are also shown (unpublished results).
AUC, ICU 
mortality
95% CI Signiﬁcance AUC, 28-day 
mortality
95% CI Signiﬁcance
MMP-8 0.644 0.539-0.750 0.008 0.572 0.489-0.654 ns
MMP-9 0.393 0.295-0.491 0.047 0.490 0.408-0.571 ns
TIMP-1 0.812 0.734-0.890 <0.001 0.687 0.608-0.766 <0.001
APACHE II 0.792 0.708-0.877 <0.001 0.704 0.624-0.784 <0.001
Maximal lactate 0.736 0.643-0.829 <0.001 0.701 0.620-0.782 <0.001
MMP=matrix metalloproteinase; TIMP= tissue inhibitor of metalloproteinases; APACHE II=Acute 
Physiology and Chronic Health Evaluation score II. AUC= area under the curve; ICU= intensive care 
unit; 95% CI= 95% conﬁdence interval. 
TIMP-1 was associated with organ dysfunction, as measured by lactate levels, which 
served as a surrogate marker for hypoperfusion. TIMP-1 correlated with the SOFA 
score on day one (rs 0.449, p>0.001) (II), and elevated levels were associated with 
increased risk for renal replacement therapy (IV). Figure 10 shows the correlation 
of admission TIMP-1 levels with maximal lactate on day 1 of the study. 
Figure 11 shows the ROC curve for TIMP-1 in predicting renal replacement therapy 
in patients with acute respiratory failure. The ability of admission TIMP-1 to predict 
renal replacement therapy was good, AUC 0.749 (95% CI 0.682-0.816) (p <0.001).
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Figure 10. Correlations of admission TIMP-1 levels with maximal lactate on day 1 of the study 
(unpublished results).
Figure 11. Admission TIMP-1 in predicting the risk for renal replacement therapy (n=56/ 371 with 
available information) in patients with acute respiratory failure (unpublished results).
72
6. DISCUSSION
6. DISCUSSION
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research, and initial experimental work led to clinical studies examining MMP 
inhibition. At the same time, it was discovered that these enzymes were important 
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'!""Q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and periodontal disease. Results from clinical studies on cancer patients turned out 
to be disappointing, but in periodontal disease the MMP inhibitor doxycycline is 
currently an FDA-approved treatment. Advances in knowledge about MMPs led to 
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acute and chronic neurological diseases and pulmonary diseases. In the late 1990s to 
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to describe the role of MMPs in critically ill patients with severe infection. In Study 
I, we then describe the presence of high levels of neutrophil-derived MMP-8 in the 
!/Q!/:''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present in another type of peritonitis, associated with CAPD (Fukudome et al. 2001), 
and thus, the presence of MMP-8 was not unexpected. It was, however, a required 
step in increasing the knowledge of the role of MMPs in acute severe infections. 
$;//"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8 levels in the systemic circulation of patients with severe sepsis or septic shock 
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II. Because the patient population in Study I was small and the study was not 
planned to investigate the association of MMP-8 with mortality, this question was 
explored in the larger population of Study II. 
6.1. MMP-8, MMP-9 AND MORTALITY
Many animal studies have shown that MMPs -8 and -9 are elevated in sepsis and 
septic shock and that inhibiting these enzymes pharmacologically may reduce sepsis-
associated organ dysfunction and mortality. This is indirect evidence of the possibly 
detrimental role of these enzymes, but the evidence is far from compelling in human 
sepsis. In Study II, we found that MMP-8 levels were higher in patients who died 
	+/;;%'
indirectly substantiated by Solan et al. (2012) in a retrospective study on a paediatric 
population, where increased synthesis of MMP-8 (MMP-8 mRNA) was associated 
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with increased 28-day mortality. The association with mortality was, however, no 
longer present in our study population when examining 28-day mortality post hoc. 
Moreover, no association with mortality was found by Gäddnäs et al. (2010) at 
any time point in a smaller one-centre study with a patient population similar to 
ours. In our larger, albeit more heterogeneous, patient population consisting of 
patients with ARF (Study IV), MMP-8 was not associated with 90-day mortality. 
From a clinical point of view, this association with early, but not late, mortality may 
reduce the interest towards MMP-8 in sepsis for a couple of reasons. First, today’s 
intensive care is effective and many of the patients who before succumbed to the 
initial shock phase now survive. Those who do not survive are often in full-blown 
';	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with death occurring rapidly despite maximal therapy. The patients who do survive 
this initial shock phase may either recover or enter a stage of sustained organ 
dysfunction and failure to recover due to “chronic critical illness” described by 
anorexia, loss of muscle mass, endocrinological changes and immunosuppression 
(reviewed by Marshall 2001 and Hotchkiss 2006). The latter is characterized by 
an inability to resolve the initial infection or susceptibility to secondary infections, 
often caused by low-virulence organisms. This group of patients comprises the 
largest number of patients dying of sepsis, not the group that succumbs to shock 
(reviewed by Hotchkiss 2006). In addition to unquestionably increased human 
suffering, this information is important in terms of health care resources. Therefore, 
ICU mortality is no longer a preferred end-point when assessing outcome, and a 
longer perspective is recommended (Bone et al. 1992). Second, in the search for 
Q"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added information to pre-existing tools and clinical assessment (Ray et al. 2010). 
In clinical practice, one of the most important questions is how can patients who 
are likely to develop organ dysfunction be found in time to prevent the detrimental 
pathophysiological chain of events. Of equal importance is to identify those patients 
who are unlikely to recover, to prevent futile care. In this respect, a biomarker like 
MMP-8 that can predict only short-term outcome may not be useful. 
On the other hand, our results are interesting from the pathophysiological point 
of view. There are several possible explanations for why MMP-8 is associated with 
early, but not late, mortality. First, it is quite clear from experimental studies that 
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is hardly surprising that the levels of the enzyme are elevated relative to healthy 
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phenomenon demonstrated in all studies of this thesis. However, in studies of 
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sepsis: initially potentially harmful by causing tissue destruction and permeability 
changes associated with, for example, neutrophil transmigration, but later possibly 
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and in subsequent repair and remodelling processes. This might be one explanation 
for why high levels of the enzyme were associated with early mortality only. More 
information could certainly be gained with serial measurements of the enzyme 
during the course of the disease.
Another important issue is what we actually measure and how we do it. In most 
studies, MMP-8 and TIMP levels are measured by ELISA, which measures the total 
amount of the enzymes and TIMPs, both bound and unbound and in latent and 
activated forms. The same applies to the IFMA assay used for MMP-8 analyses in 
Studies I, III and IV. At the moment, no simple quantitative analysis method for 
the active form of the enzyme is available. Understanding the role of MMP-8 would 
be enhanced by such measurements because only the biologically active enzyme is 
likely to be relevant. MMPs are under strict control by several mechanisms. In the 
"'''/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levels of TIMP-1 and possibly other TIMPs not measured are also elevated to a high 
extent. Given the simultaneous upregulation of other MMPs, like MMP-9 and others, 
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of active enzymes in the circulation or locally. Of course, the high circulating levels 
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in all the interpretation of concentrations must be done cautiously. To circumvent 
this problem, some studies have used the ratio of MMP and TIMP as a surrogate 
measure of enzyme activity, but the above-mentioned overlap in the inhibitory 
function of TIMPs on MMPs makes this questionable. This critique is even more 
relevant considering studies using MMP-8 mRNA as a predictive tool. 
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II was that non-survivors had lower serum levels of MMP-9 than survivors. Only 
one small, earlier study on septic patients has reported higher MMP-9 levels in 
non-survivors (Nakamura et al. 1998); as others have found no difference, or in one 
large study, lower levels in non-survivors (Lorente et al. 2009). This makes MMP-
9 a poor biomarker candidate because its levels are low both in healthy controls 
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the host eradicate invading micro-organisms, one may speculate that a certain 
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help neutrophils to carry out this function could lead to worse outcomes. It would, 
however, be too simplistic to conclude that MMP-9 is merely protective in sepsis 
on the basis of these results, for several reasons. First, in two studies MMP-9 levels 
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were associated with measures of organ dysfunction (Lorente et al. 2009, Gäddnäs 
et al. 2010), although a negative correlation also has been reported (Yazdan-Ashoori 
et al. 2011). Second, many experimental studies again suggest that in MMP-9 knock-
out animals or by using an MMP inhibitor the outcome may be improved. Third, 
the cellular origin of MMP-9 is different from that of MMP-8. Whereas MMP-8 is 
mainly neutrophil-derived, various other cell types can be induced to produce MMP-
Q>!"""%/::"/
probably followed by a secondary induction and upregulation at the tissue level, 
which may not yet (if ever) be visible in systemic samples taken during early phases 
at the ICU. This challenges us to study the time course of different MMPs and their 
inhibitors during ICU treatment and to search for a difference in change over time 
in concentrations between patients with favourable and unfavourable outcomes. 
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They did not, however, report any mortality data. In another study, Yadzan-Ashoori 
et al. (2011) found similarly high MMP-9 levels on day 1, with a subsequent decline. 
Especially in case of markers elevating very early, it should be noted that admission 
as a time-point for sampling is also a diffuse concept. Timing calculated from the 
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depends on timing of examination, and we may never reach patients at exactly the 
same phase of the disease, with the exception of absolute events such as trauma, 
burns, cardiac arrest or elective operations. This restricts the information that can be 
gained by taking a single snapshot-like sample during a dynamic process like SIRS. 
6.2. INHIBITION OF MMPS IN SEPSIS
Experimental studies almost uniformly show less tissue destruction, less organ 
dysfunction and an improved outcome by using an MMP inhibitor. This has also 
been the case with many other mediators, which have subsequently been tried in 
clinical trials with disappointing results. There are, of course, crucial differences 
between experimental animal models and human sepsis, beginning with differences 
between species and the poor equivalence of sepsis models, especially endotoxin 
models, with human infection. Importantly, the timing of inhibitor dosage is almost 
always very early, if not prophylactic, in these studies. This enables the inhibitor to 
exert its actions very early in the cascade, which is not the case in clinical reality. 
%;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of an MMP inhibitor (Steinberg et al. 2003, Meli et al. 2006, Leib et al. 2001). 
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Finally, the follow-up in experimental studies is almost always short and does not 
give us answers about the long-term effects of inhibitors. 
The results of this study do not directly answer the question of whether MMP-8 
and -9 are ultimately harmful or not. Given that they are elevated in the early phase of 
!"";;":::'!""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cascades and are associated with early mortality, a certain degree of inhibition in 
very severe shock could be useful. It has been suggested that doxycycline, which 
inhibits MMPs only partly, could be used in low sub-antimicrobial doses to eliminate 
: !"" ;"/':
reparative functions (Sorsa et al. 2006). Since doxycycline is a well-known antibiotic 
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al. 2012), a randomized placebo-controlled double-blinded pilot study with early, 
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should, however, be kept in mind, namely the possible antagonism of a bacteriostatic 
and a bactericidal antibiotic. In 1951, Lepper et al. reported increased mortality 
when a tetracycline was combined with a beta-lactam antibiotic in treatment of 
pneumococcal meningitis in a study of 14 patients. Similar results were reported 
"/<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effect of doxycycline as an adjuvant therapy with ceftriaxone was demonstrated 
in an experimental model of pneumococcal meningitis despite an in vitro partial 
antagonism of the antibiotics demonstrated in the same study (Meli et al. 2006). 
It might, however, be wise not to extend the pilot studies to include patients with 
pneumococcal meningitis. 
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6.3. TIMP-1 AND MORTALITY
In Studies II and IV, systemic levels of TIMP-1 were associated with increased 
mortality. TIMP-1 was included in the analyses because of its important role as 
an inhibitor of MMP-8 and MMP-9. The results were somewhat unexpected, 
considering the assumed harmful role of MMPs, not their inhibitors. There are, 
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et al. 2006, Lorente et al. 2009) as well as patients with acute lung injury (Ricou 
et al. 1996). Regarding ALI/ARDS, a low ratio of MMP-9/TIMP-1 in BAL was 
associated with more severe course of the disease (Lanchou et al. 2003, Ricou et 
al. 1996). Furthermore, TIMP-1 was independently associated with increased all-
cause and cardiac mortality and with the incidence of myocardial infarction in a 
24-month follow-up study of 389 male patients undergoing coronary angiography 
for variable reasons (Cavuosglu et al. 2006). It also predicted major adverse cardiac 
events in a large prospective observational study on myocardial infarction patients 
(Kelly et al. 2010). TIMP-1 is predictive of outcome also in some malignant diseases 
(Holten-Andersen et al. 2006, Nakopoulou et al. 2002). In Study IV the ability of 
TIMP-1 to predict mortality was fairly good also in electively operated patients 
needing mechanical ventilation for more than 6 hours. In Study II, the association 
was not analysed in detail, but in post hoc analyses the overall predictive ability was 
good, even better than that of the well-known APACHE II and SOFA scores and 
maximal lactate levels. This suggests that TIMP-1 should be further validated as a 
biomarker in predicting outcome and possibly separately in predicting dysfunction of 
different organ systems. In Study IV, a post hoc/"
patient characteristics and organ dysfunction in detail, suggested that TIMP-1 
levels predicted need for renal replacement therapy. TIMP-1 levels also correlated 
highly with lactate levels in our Study II population, suggesting an association with 
hypoperfusion or disturbances in oxygen delivery or utilization. Interestingly, in 
one study, TIMP-1 was associated independently with left ventricular systolic 
dysfunction (Cavuosglu et al. 2006). Moreover, TIMP-1 was associated with the 
degree of oxygenation disturbance in Study IV. 
The explanation for the association of TIMP-1 with poor outcome may or 
may not lie in MMP inhibition; however this cannot be resolved by our results. 
TIMP-1 has been associated with increasing age (Holten-Andersen et al. 2006, 
   = Q "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hypertension (Kelly et al. 2010). TIMP-1 has also been shown to have functions 
that are independent of its MMP inhibitory capacity, such as erythroid potentiating 
';":'>Q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al. 2010). It is also involved in steroidogenesis and is anti-angiogenic (reviewed 
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et al. 1997). An interesting feature of TIMP-1 with sepsis is its ability to activate 
neutrophils, inhibit their transmigration and inhibit neutrophil apoptosis (Chromek 
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and thus, impaired prognosis. TIMP-1 is anti-apoptotic also for B-lymphocytes 
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in critically ill patients requires more detailed experimental studies, where the focus 
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organ level. Evidence is accumulating that a high degree of immune cell apoptosis, 
particularly of T lymphocytes, is of great relevance in the development of a sepsis-
associated immunosuppressive state and impaired prognosis (Hotchkiss et al. 1999). 
6.4. MMPS AND TIMP-1 IN CARDIAC ARREST PATIENTS
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arrest patients and the association of mild therapeutic hypothermia with lower 
levels of MMP-9. The elevated MMP levels in this patient group can be interpreted 
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that non-infectious processes, such as ischaemia-reperfusion, may activate the 
metalloproteinase synthesis and/or release.
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9 in cardiac arrest patients. It gives more insight into the mechanisms underlying 
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results from a study using a swine model of cardiac arrest and MTH. They found 
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suppressed mRNA expression of NF-kappaB, MMP-9 and aquaporin-4 in cortical 
tissues at 24 hours from ROSC. TIMP-1 was elevated in the hypothermia group, but 
no differences were found in IL-6 or IL-10 between groups. Their study also found 
no differences after hypothermia at 48 hours from ROSC. Interestingly, TIMP-1 
has been shown to exert neuroprotection after glutamate exitotoxicity in vitro by 
a mechanism apparently independent of its MMP inhibitory function (Tan et al. 
2003). 
Because the samples analysed in our study were obtained from a study not 
originally designed for investigating MMPs, there are several possible confounding 
factors. MMP levels in our study may have been affected by the underlying cardiac 
disease or treatment. MMPs, MMP-8 and MMP-9 in particular, are important 
proteinases associated with atherosclerosis and destabilization of atherosclerotic 
plaques (Herman et al. 2001). Elevated systemic MMP-8 (Kato et al. 2005) and 
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MMP-9 levels are present in stable coronary artery disease, acute coronary syndromes 
(Blankenberg et al. 2003) and subsequent left ventricular dysfunction (Squire et al. 
2004). Elevated MMP-8 (Tuomainen et al. 2007) and MMP-9 (Blankenberg et al. 
2003, Hansson et al. 2011) are associated with an increased risk of cardiovascular 
death. Furthermore, the thrombolytic agent tPA is an MMP-9 activator (Horstmann 
et al. 2003). Smokers have higher MMP-8, TIMP-1 (Tuomainen et al. 2007) and 
MMP-9 levels, whereas statin users have lower levels (Blankenberg et al. 2003). 
Moreover, the patients may have had underlying acute or chronic infections that 
affected the MMP levels. On the other hand, CRP levels were generally very low. 
Considering these possible confounders, our results should be interpreted mainly 
as hypothesis-generating material. 
6.5. SYSTEMIC MMP-8 IN ACUTE RESPIRATORY FAILURE
Acute respiratory failure patients and ALI/ARDS patients in particular were 
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permeability changes in the pathophysiology of the disease. The evidence regarding 
MMP-9 involvement in lung injury pathophysiology was moderate in the literature, 
and thus, the failure of the other neutrophil-derived enzyme MMP-8 as a biomarker 
was somewhat disappointing. One explanation for the failure could be that the 
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found that the levels of MMP-8 in the infected compartment correlated poorly 
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performing BAL is not a simple procedure suitable for screening, we chose to 
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systemic MMP-8 has been investigated in acute respiratory failure patients. Some 
studies have examined systemic levels of MMP-9 (Pugin et al. 1999, Ricou et al. 
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patient population with differing background diagnoses is another explanation. Not 
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that MMP-8 has a dual, U-shaped relation to mortality.
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6.6. STRENGTHS AND LIMITATIONS OF THE STUDY
The strengths of this study lie in results that are novel and create new hypotheses 
of the role of MMPs and especially TIMP-1 in critical illness. Clinical research 
$$@%	$@"//":
diagnostic groups. There are, however, several limitations of this study that need 
to be addressed.
The sample size in Study I was small. Because no previous studies existed, a power 
analysis was not performed, and the sample size was based on convenience (>10 
patients). A larger sample size could have strengthened the results. The timing of 
the samples was relatively late in the course of the disease, and serial measurements 
of MMP-8 during the course of the disease would have been valuable. Furthermore, 
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given more insight into the role of MMPs in secondary peritonitis. However, this 
design allowed us to describe a new phenomenon, which was the original purpose 
of the study. In Study II, instead of a single measurement, serial measurements of 
the variables would have enhanced our understanding of the dynamics of MMPs and 
TIMP-1 in severe sepsis and septic shock. Development of MMP and TIMP-1 levels 
over the course of the disease could have better helped us to assess the association 
/'"?/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;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organ systems would have been of value. This is a subject for future studies that 
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this study is that the statistical analyses were not planned to examine the predictive 
power of our variables, but concentrated on the comparison of variables´ levels 
between survivors and non-survivors. Furthermore, hospital mortality or, rather, 
90-day mortality should have been preferred as a primary outcome measure. Last, 
we used the same control group as in Study I, which is a limitation because the 
storage time of the samples was thus different.
Study III was small and retrospective. On the other hand, it would probably 
not be possible today to design a prospective study with a non-hypothermia-
treated control group because of the wide implementation of MTH treatment 
;;':Q%"&";/Q
regardless of the limitations. The most apparent weakness in this study was the 
lack of baseline blood samples. Therefore, the possibility that the variables´ levels 
may have been different at baseline, before the hypothermia treatment, cannot be 
excluded. Because the samples were taken at time-points calculated from ROSC, 
the duration of hypothermia treatment at the time-points used may have varied. 
Furthermore, samples from all patients from the original study were not available. 
Thus, although the patients were similar when tested, they may have been different in 
some respect. The relatively long storage time before analysis may also have affected 
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our results, although the difference between groups would be expected to be smaller 
in that case. The sample size was too small for any analyses considering outcome. 
These limitations render the results of this study only hypothesis-generating and 
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inclusion of a wide variety of diagnostic groups that did not necessarily suffer from 
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limitations may have biased our results and weakened the possibility of interpreting 
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The group of healthy controls was small and the controls were younger than 
the patients in all studies. 
6.7. PRE-ANALYTICAL CONSIDERATIONS
Measuring MMPs, particularly MMP-9, in serum samples has been questioned 
in recent literature because the serum levels of the enzyme are higher than when 
using anticoagulated blood. This has been explained by a release of MMP-9 from 
neutrophils or activated platelets during the sampling process or coagulation 
(Makowski et al. 2003). The lowest MMP-9 levels are found when using citrated 
plasma (Makowski et al. 2003). The difference between plasma and serum is 
evident when comparing the proportion of active enzyme, but when measuring 
the total amount of the enzyme (pro- and activated form), the levels are correlated 
between each sampling system (Gerlach et al. 2007), and thus, within one study 
the use of any method can be considered acceptable. However, in future studies, 
use of citrated plasma is preferable. Additionally, freeze-thaw cycles of seven or 
more affect the enzyme levels (Souza-Tarla et al. 2005). In our studies, all the 
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et al. (2007). 
6.8. ETHICAL CONSIDERATIONS
All of the study protocols were approved by their respective ethics boards. Informed 
consent was obtained for sample taking (I, II, IV). For Study III, a deferred consent 
was used in the original study, and all patients or their legal surrogates accepted 
the protocol and sample-taking. All patients received standard care during the 
studies (I, II, IV). In study III, the patients received standard or what was at that 
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protocols (I, II, IV) consisted of sample collection only. The sample collection likely 
did not cause discomfort, pain or harm to the patients because pre-existing lines or 
tubings were used. These studies can therefore be considered ethically acceptable. 
6.9. FUTURE ASPECTS
Despite increasing interest, only a few clinical studies describing the course of 
MMPs and their inhibitors in different infections exist. Well-designed studies are 
needed to demonstrate the presence and time course of MMPs and TIMPs and 
!""";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such as meningitis, pneumonia and peritonitis. Diagnostic implications are possible. 
Based on the apparently poor correlation of systemic and local levels of MMPs, these 
studies could primarily focus on measuring enzyme levels at the compartment level. 
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bacterial meningitis and patients with a non-infectious indication for CSF sampling. 
Demonstration of differing levels between groups could lead to development of a 
test to differentiate bacterial infection from other conditions. The advantage in 
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MMP test could aid in prompt selection of a therapy. To be advantageous, detecting 
MMPs would presuppose a rapid quantitative or semi-quantitative test. Indeed, 
a rapid (within15 minutes) quantitative chair-side test for detecting MMP-8 in 
periodontitis patients has been developed, and the results are in line with traditional 
assays such as IFMA (Sorsa et al. 2010.) In addition to odontology, the applicability 
of this analytical method could be tested in other settings as well. Analyses of body 
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applied to examine the comparability of the methods and then test the sensitivity 
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planned for intubated patients with suspected VAP, where MMP levels in tracheal 
aspirates have been suggested to differentiate true VAP from non-VAP (Wilkinson 
et al. 2012). First, MMP-8 (and -9) could be determined and compared with a 
patient group without VAP, e.g. intubated operative patients. Then, as in suspected 
meningitis, a bed-side test and IFMA could be compared. If comparable, the bed-
side test should then be validated against a gold standard in a different patient 
population. However, the determination of a reliable gold standard in diagnosing 
VAP is pending. The diagnostic approach could be further expanded to peritonitis 
:"':''!/'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of the liver.
A randomized controlled double-blinded pilot study on the effects of an MMP 
inhibitor doxycycline on severe sepsis patients should be designed. Such a study 
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should examine also the pharmacokinetics of intravenous doxycycline in this patient 
group. Critically ill patients have an increased volume of distribution, and thus, the 
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where the oral route of administration has been used. Using the intravenous route, 
the dose is unknown. Plasma levels of MMPs and doxycycline should be measured 
serially during and after a short-term intervention of 3-5 days and the MMP levels 
in treatment and placebo groups compared. All adverse events should be carefully 
registered. If a dosage with acceptable safety levels and a measurable effect on 
MMP concentrations is found, a larger RCT should be designed to investigate the 
association of doxycycline treatment with such outcome measures as survival and 
development of organ dysfunction.
Today little is known about the role of MMP-8 and -9 in the development of 
sepsis-associated organ dysfunction. Recently, MMP-8 was suggested to predict the 
development of sustained acute kidney injury (Basu 2011). A good early marker for 
the risk of developing AKI is needed in order to stratify patients to clinical studies 
and treatment protocols. In search of such a marker, MMPs should be measured 
in plasma and urine of ICU patients and their ability to predict AKI evaluated. On 
the basis of our preliminary, unpublished analysis in Study IV patients, also TIMP-1 
could be a promising biomarker for predicting AKI. Experimental evidence of the 
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encourages studies analysing MMP levels in association with DIC. 
MMPs -8 and -9 are currently being studied in a patient group characterized by 
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patients with severe burns. The hypothesis is that MMPs contribute to the increased 
permeability and shock associated with severe burns. Plasma, urine and, if present, 
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of the total body surface area are compared with patients with less severe burns 
and healthy controls, and the association of MMP levels with organ dysfunction is 
analysed. The ultimate goal of studies in this patient group is a subsequent study 
of MMP inhibition, but further planning requires detailed characterization of the 
role of MMPs in injury. Also their role in reparative processes and wound healing 
must be characterized.
Another diagnostic group with a limited amount of studies and a likely MMP-
8 and -9 involvement is severe acute pancreatitis (SAP). New studies are needed 
because the treatment of SAP remains exclusively supportive. First, high levels 
of MMPs in acute pancreatitis patients should be demonstrated, comparing the 
patients with either healthy controls or patients with less-severe, self-limiting 
'%/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least preliminary analysis of disease severity and outcome. If an association of high 
MMP-8 or-9 levels with increased mortality is found, this patient group could be 
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in experimental studies. Furthermore, in pancreatitis, no infection is present in the 
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impaired bacterial clearance in the early phase.
In the future, serial measurements over the course of ICU treatment of 
MMP-8 and MMP-9 in cardiac arrest patients should be performed and the 
association with outcome assessed in a large prospective patient population. If 
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of further studies on MMP inhibition as well. In experimental stroke studies, an 
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decreased markers of apoptosis (Liu et al. 2008). In another study on experimental 
stroke, minocycline, which is a lipophilic tetracycline group antibiotic with MMP-
inhibiting activities, reduced infarct size and permeability changes as effectively as 
hypothermia treatment (Nagel et al. 2008). The effects of minocycline compared 
with hypothermia treatment should be examined also in an experimental cardiac 
arrest model. After this, a pilot RCT comparing the combination of minocycline and 
standard treatment with standard treatment alone could be designed to evaluate 
the potential synergistic effect of the treatments.
More experimental studies examining the role and regulation of TIMP-1 in the 
: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whether the high levels of TIMP-1 in sepsis are adaptive, or whether TIMP-1 has 
a detrimental role. The association of TIMP-1 with dysfunction of different organs 
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factors are associated with elevated TIMP-1. 
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a novel approach to sepsis, the PIRO model, has been proposed (Levy et al. 2003). 
PIRO attempts to create a staging, analogous to the established TNM staging used in 
oncology. The purpose of PIRO is to better stratify the patients to groups according 
to their predisposition (P), type of infection or insult (I), response (R) and organ 
:/'<=<;=%/'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staging tool reported equivalence of the PIRO model to the traditional severity 
scorings (Rubulotta et al. 2009). However, in their model, no biomarkers were used. 
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genomic information in the “P” and biomarkers in the “R” components (Rubulotta 
et al. 2009). Clinical studies should focus on examining whether measuring TIMP-
1 adds to the present models of outcome prediction. They could aim at creating 
new panels composed of TIMP-1 and other novel biomarkers to be incorporated 
in PIRO or other staging tools. Thus far, no individual biomarker in sepsis has 
proven superior to another. Within the FINNSEPSIS study, several biomarkers have 
been examined, such as VEGF (Karlsson et al. 2008), procalcitonin (Karlsson et al. 
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2010), N-terminal pro-brain natriuretic peptide (Varpula et al. 2007), cell-free DNA 
(Saukkonen et al. 2008), chromogranin A (Røsjø et al. 2012) and high-sensitivity 
troponin T (Røsjø et al. 2011). Compared with the results of these studies, TIMP-
1 in our study shows the best performance in predicting ICU mortality. Of the 
biomarkers tested in the FINNSEPSIS population, chromogranin A has the best AUC 
in predicting hospital mortality (Røsjø et al. 2012). In other patient populations, IL-6 
(Pettilä et al. 2002) and suPAR (Koch et al. 2011) have shown promising results, 
although IL-6 was not an independent predictor of mortality (Pettilä et al. 2002). 
In comparing our results with other studies on the FINNALI patients, TIMP-1 in 
our study performed superiorly to suPAR (Jalkanen et al. 2012), comparably to 
plasma cell-free DNA (Okkonen et al. 2011a), and inferiorly to N-terminal pro-
brain natriuretic peptide (Okkonen et al. 2011b) in predicting 90-day mortality. In 
a recent study, Calfee et al. (2011) created and validated a panel of biomarkers for 
predicting mortality in acute lung injury. They found that a panel of admission values 
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necrosis factor receptor-1 and surfactant protein-D, improved diagnostic accuracy 
when added to APACHE III, compared with APACHE III alone. The usefulness 
of creating a panel of the moderately performing biomarkers derived from the 
FINNALI study, including TIMP-1 should be examined in a clinical study. 
A new era in the search for potential new biomarkers has already begun with 
the novel microarray and proteomics techniques that are able to screen a large 
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7. CONCLUSIONS
7. CONCLUSIONS
1. Systemic levels of MMP-8 and MMP-9 are elevated in various groups of critically 
ill patients compared with healthy controls, regardless of whether the initiating event 
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sepsis or septic shock patients, but reduced levels are seen after cardiac arrest 
compared with healthy controls. 
2. High levels of mainly neutrophil-derived MMP-8 are present in the peritoneal 
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3. Elevated systemic MMP-8 and TIMP-1 are associated with increased ICU mortality 
in patients with severe sepsis or septic shock. Among these patients, MMP-9 levels 
are lower in ICU non-survivors than in ICU survivors. 
 
4. Systemic MMP-8 is not useful in predicting 90-day mortality in patients with 
acute respiratory failure. TIMP-1 is a potentially useful biomarker with a moderate 
discriminative power in predicting 90-day mortality in acute respiratory failure 
patients. 
5. Serum MMP-9 levels are lower in patients treated with mild therapeutic 
hypothermia than in patients receiving non-hypothermia treatment. Levels of MMP-
$$@>J%	$@>''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group compared with controls.
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